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ABSTRACT
Although trehalose has recently gained interest because of its pharmaceutical potential, its clinical use is
hampered due to its low bioavailability. Hence, hydrolysis-resistant trehalose analogues retaining bio-
logical activity could be of interest. In this study, 34 4- and 6-O-substituted trehalose derivatives were syn-
thesised using an ether- or carbamate-type linkage. Their hydrolysis susceptibility and inhibitory properties
were determined against two trehalases, i.e. porcine kidney and Mycobacterium smegmatis. With the
exception of three weakly hydrolysable 6-O-alkyl derivatives, the compounds generally showed to be com-
pletely resistant. Moreover, a number of derivatives was shown to be an inhibitor of one or both of these
trehalases. For the strongest inhibitors of porcine kidney trehalase IC50 values of around 10mM could be
determined, whereas several compounds displayed sub-mM IC50 against M. smegmatis trehalase. Dockings
studies were performed to explain the observed influence of the substitution pattern on the inhibitory
activity towards porcine kidney trehalase.
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Carbohydrates are the most diverse and abundant biomolecules
on earth, displaying a wide variety of functions1. During the last
decades, interest arose in trehalose 1 (Figure 1), a disaccharide
consisting of two D-glucose units linked via an a-1,1-a-bond,
resulting in a molecule with unique stabilising properties2,3. The
stability of this non-reducing glucobiose is reflected by several
interesting physicochemical properties like broad pH stability4,
high glass transition and melting temperatures5,6, low hydrolysis
rate5. During heating and processing of food products acrylamide
formation can be suppressed by trehalose as it interacts with glu-
cose and thus reduces the glucose-Asn reaction leading to the
toxic compound4,6. In nature, trehalose fulfils a biological role in
various organisms including bacteria, yeast, fungi, insects, inverte-
brates and plants, although it is not found in mammals6,7. It can
serve as energy and carbon source6,7, signalling molecule6,8,9 and
cell wall building block6,10. Furthermore, it can protect organisms
and compounds under stress conditions like desiccation7,11,12,
dehydration7,13–15, heat7,13, cold7 and oxidation7,14.
Since the establishment of the Hayashibara process, the avail-
ability of trehalose has drastically increased, leading to its wide-
spread use in the food, cosmetic and pharmaceutical industry6.
Moreover, due to its safeguarding capabilities, trehalose has
received attention as a chemical chaperone16,17 and autophagy
inducer16 in the treatment of neurodegenerative diseases like
Alzheimer’s18,19, Huntington’s20 and Parkinson’s16,21,22.
Unfortunately, the therapeutic use of trehalose is hampered due
to its low bioavailability. Indeed, this disaccharide is rapidly
degraded into glucose by the trehalase (EC 3.2.1.28) present in
our small intestine23. Trehalose analogues and derivatives that
show resistance against this human intestinal enzyme could,
therefore, be of great interest for pharmaceutical formulations and
for drug discovery due to their increased residence time in the
human body3,23. Recently, a trehalose analogue substituted on the
4-hydroxy group, lentztrehalose A 2 (Figure 1), was isolated from
the actinomycete Lentzea sp. and was shown to be only weakly
hydrolysed by porcine kidney trehalase24. Furthermore, it also
exhibited antitumor activity24. Subsequently, Wada and co-workers
isolated two additional natural analogues, lentztrehalose B 3 and
C 4 (Figure 1), which were shown to be possible inducers of
autophagy25. Importantly, these lentztrehaloses were found not to
be digested in a range of microbes and cancer cell lines, and their
in vivo bioavailability and stability was confirmed after oral admin-
istration to mice26.
In this study, an exploration of 34 trehalose derivatives (includ-
ing 33 new compounds next to lentztrehalose A 2) was estab-
lished. Inspired by the lentztrehaloses A-C 2–4, a series of 4-O-
substituted trehalose derivatives was synthesised using an ether-
or carbamate-type linkage. In addition, the analogous 6-O-substi-
tuted series was explored while some double substituted deriva-
tives were also investigated. Their biological relevance was
assessed by measuring their hydrolysis (as substrate) and binding
(as inhibitor) with two relevant trehalases, i.e. porcine kidney tre-
halase (91% similarity with human trehalase) and Mycobacterium
smegmatis trehalase (93% similarity with M. tuberculosis trehalase).
These enzymes are classified in family GH37 and GH15, respect-
ively, of the CAZy-classification. Although they adopt a similar
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overall fold (i.e. an (a/a)6-barrel) and follow the same general reac-
tion mechanism (i.e. inversion of the anomeric configuration
through single displacement), they are otherwise unrelated (about
20% similarity). Computational studies were performed to clarify
the structural determinants behind the activities and selectivity





All reactions, unless otherwise stated, were carried out under
argon atmosphere in dry solvents. Dichloromethane and triethyl-
amine were freshly distilled from CaH2. Toluene was freshly dis-
tilled from Na. Tetrahydrofuran was freshly distilled from Na/
benzophenone. Other solvents and reagents were obtained from
commercial sources and were used as received without further
purification. Flash chromatography was carried out with Rocc sili-
cagel 60 Å, 4063mm. Precoated silica gel plates (Macherey-Nagel
SIL G-25 UV254) were used for TLC employing UV-absorption at
254 nm and Mo7O24/Ce(SO4)2/aq.H2SO4 staining for visualisation.
Electrospray mass spectra were recorded on an Agilent 1100 series
single quadrupole MS detector type VL with an APCI source and
an API-ES source, provided with a Phenomenex Luna C18 (2),
5 mm 250mm  4.60mm column. High resolution mass spectrom-
etry (HRMS) was performed on an Agilent 1100 series connected
to a 6220A TOF-MS detector equipped with an APCI-ESI multi-
mode source. 1H-NMR and 13C-NMR spectra (see Supplementary
information) were recorded on a Bruker Avance 300, Bruker
Avance 400 or a Bruker AM 500 spectrometer as indicated with
chemical shifts reported in parts per million, referenced to the
residual solvent signals (CDCl3: 7.26 and 77.00 ppm, D2O:
4.75 ppm, CD3OD: 3.31 and 49.15 ppm, benzene-d6: 7.16 and
128.0 ppm, DMSO-d6: 2.50 and 39.43 ppm, acetone-d6: 2.05 and
29.84 ppm). 13C-NMR Spectra recorded in D2O were referenced to
the signal (30.89 ppm) of acetone (1 drop added). Coupling con-
stants, J, are reported in hertz (Hz). Infra-red spectra were
recorded on a Perkin-Elmer 1000 FT-IR infra-red spectrometer
(horizontal attenuated total reflection (HATR)). Optical rotation
was measured on a Perkin Elmer 241 Polarimeter.
General procedure A: O-alkylation
To a solution of an OH-containing starting material in anhydrous
DMF (0.1M concentration) was added NaH (60% in mineral oil, 2.5
eq for each hydroxyl group). After stirring for 15min, the alkyl halo-
genide (4 eq for each hydroxyl group) was added and the reaction
mixture was stirred overnight. Methanol (5ml per mmol starting
material) was added dropwise (caution: gas formation) and the mix-
ture was transferred to a separation funnel using EtOAc (50ml per
mmol starting material). The organic layer is washed with brine (5,
50ml per mmol starting material) and concentrated under reduced
pressure. The residue was purified by column chromatography.
General procedure B: carbamate formation
To a solution of an OH-containing starting material in CH2Cl2
(0.1M concentration) was added DMAP (0.2 eq for each hydroxyl
group) and the isocyanate (3 eq for each hydroxyl group). The
reaction mixture was stirred at room temperature until the con-
sumption of starting material (TLC monitoring, 24–120 h). The mix-
ture was concentrated under reduced pressure and the residue
was purified by column chromatography.
General procedure C: hydrogenolysis
To a solution of a benzyl/benzylidene-protected starting material
in EtOAc/MeOH (1/1, 0.05M concentration), Pd/C (10% w/w Pd,
Figure 1. Structure of trehalose 1 and lentztrehalose A-C 2–4.
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0.05 eq) was added. A H2 balloon was placed and the reaction
mixture was stirred overnight after which it was filtered over cel-
ite. The filtrate was concentrated under reduced pressure and the
residue was purified by column chromatography.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-a,a-D-trehalose (7)
To a cooled (18 C) solution of 629 (5.576 g, 6.35mmol, 1 eq) in
toluene (56ml), DIBAL-H (supplied as 1.0M solution in toluene,
31.9ml, 31.9mmol, 5 eq) was added dropwise. The cooling bath
was removed and the reaction mixture was stirred at room tem-
perature for 90min. The solution was cooled to 0 C and the reac-
tion was quenched by dropwise addition of MeOH (11.5ml) and
aqueous KOH (10% w/v, 3.75ml). The resulting suspension was
transferred to a separation funnel using CH2Cl2 (400ml) and H2O
(400ml). The organic layer was separated and the aqueous phase
was extracted using CH2Cl2 (3 400ml). The combined organic
layers were dried on MgSO4, the drying agent was filtered and
the filtrate was concentred under reduced pressure. The residue
was purified by flash column chromatography (gradient elution:
hexane/EtOAc 8/2 to 1/1) to obtain the title compound 7 as a
white foam with a yield of 80% (4.443 g; 5.05mmol). Spectral data
were in agreement with literature27.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-a,a-D-trehalose (8)
and 2,3,6,2’,3’,6’-hexa-O-benzyl-a,a-D-trehalose (9)
To a cooled (0 C) solution of 627 (2.000 g, 2.28mmol, 1 eq) in
CH2Cl2 (2.0ml), DIBAL-H (1.0M solution in CH2Cl2, 11.4ml,
11.4mmol, 5 eq) was added dropwise. After stirring for 90min at
0 C, the clear colourless reaction mixture was diluted with CH2Cl2
(20ml) and the reaction was quenched by dropwise addition of
MeOH (6ml). Subsequently, aqueous KOH (10% w/v, 6ml) was
added and the resulting suspension was transferred to a separ-
ation funnel using CH2Cl2 (250ml) and H2O (250ml). The organic
layer was separated and the aqueous phase was extracted with
CH2Cl2 (2 250ml). The combined organic layers were dried on
MgSO4, the drying agent was filtered and the filtrate was concen-
trated under reduced pressure. The residue was purified using col-
umn chromatography (gradient elution: hexane/EtOAc 8/2 to 6/4).
Following products were isolated (in order of elution): recovered
starting material 6 (200mg, 0.228mmol, 10%), compound 8 (4-
OH, 1.107 g, 1.256mmol, 55%), compound 9 (4/40-bis-OH, 179mg,
0.203mmol, 9%) and compound 7 (6-OH, 380mg, 0.431mmol,
19%). Rf values in hexane/EtOAc 7/3: Rf 0.36 (6), Rf 0.31 (8), Rf
0.25 (9), Rf 0.11 (7). Spectral data of compounds 828 and 929 were
in agreement with the literature.
2,3,4,2’,3’,4’-Hexa-O-benzyl-a,a-D-trehalose (10)
To a cooled solution (0 C) of 7 (620mg, 0.704mmol, 1 eq) in tolu-
ene (6.32ml), DIBAL-H (1.0M in toluene, 3.52ml, 3.52mmol, 5 eq)
was added dropwise. After 15min, the ice bath was removed and
the reaction mixture was stirred for 24 h. After cooling to 0 C,
MeOH (1.3ml) and 10% aqueous KOH (0.4ml) were added, and
the resulting mixture was transferred to a separation funnel using
CH2Cl2 (40ml) and H2O (40ml). The organic layer was separated
and the aqueous layer was extracted with CH2Cl2 (2 40ml). The
combined organic layers were washed with brine (50ml) and con-
centrated under reduced pressure. The residue was purified via
column chromatography (gradient elution: hexane/EtOAc 7/3 to 4/
6), affording the title compound 10 as a white foam (491mg,
0.556mmol, 79%). Rf 0.14 in hexane/EtOAc 1/1. Spectral data were
in agreement with the literature28.
2,3,4,6,2’,3’-Hexa-O-benzyl-4’,6’-O-benzylidene-a,a-D-trehalose (11)
Method 1: via benzylation of 7. To a solution of 7 (414mg,
0.470mmol) in anhydrous DMF (4.7ml), NaH (60% in mineral oil,
78mg, 1.17mmol, 2.5 eq) was added slowly resulting in gas for-
mation. The grey suspension was cooled to 0 C and BnBr (113 mL,
0.94mmol, 2 eq) was added dropwise. Next, TBAI (12mg,
0.032mmol, 0.07 eq) was added and the ice bath was removed.
After stirring overnight, the reaction mixture was cooled to 0 C
and carefully quenched (gas formation) with MeOH (2ml). After
15min, the mixture was diluted with ethyl acetate (35ml) and
transferred to a separation funnel. The organic phase was washed
with brine (3 30ml), and dried on MgSO4. The drying agent was
filtered and the filtrate was concentrated under reduced pressure.
The crude product was purified by flash column chromatography
(gradient elution: hexane/EtOAc 9/1 to 8/2) giving the title com-
pound 11 as a white solid (yield: 73%, 328mg). Spectral data
were in agreement with literature29.
Method 2: alternative route via 14. To a suspension of anhyd-
rous trehalose (15 g, 43.82mmol) and camphorsulfonic acid
(0.70 g, 2.19mmol, 0.05 eq) in DMF (90ml) benzaldehyde dimethyl
acetal (6.57ml, 43.82mmol, 1 eq) was added and the mixture was
heated to 90 C for 15min. To the resulting colourless solution,
triethylamine (6.90ml, 49.5mmol, 1.1 eq) was added and the mix-
ture was concentrated under reduced pressure. The crude 4,6-O-
benzylidene-a,a-D-trehalose (13) (21.17 g) was dissolved in pyri-
dine/acetic anhydride (1/1, 80ml) and the reaction mixture was
stirred for 24 h after which the volatiles are removed under
reduced pressure. The crude product was purified by column
chromatography (gradient eluent ion hexane/EtOAc 8/2 to 6/4)
giving 2,3,4,6,20,30-hexa-O-acetyl-40,60-O-benzylidene-a,a-D-trehal-
ose (14) as a white solid with a yield of 34% over two steps
(10.17 g, 14.90mmol).
14: Rf 0.28 in hexane/EtOAc 1/1. 1H NMR (400MHz, acetone-
d6): d 7.48–7.42 (m, 2H), 7.38–7.33 (m, 3H), 5.67 (s, 1H), 5.60 (t,
J¼ 9.9 Hz, 1H), 5.53 (t, J¼ 9.5 Hz, 1H), 5.40 (d, J¼ 3.9 Hz, 1H), 5.34
(d, J¼ 3.8 Hz, 1H), 5.10–5.00 (m, 3H), 4.28–4.15 (m, 3H), 4.11–4-03
(m, 2H), 3.94 (t, J¼ 9.6 Hz, 1H), 3.86 (t, J¼ 10.3 Hz, 1H), 2.12 (s, 3H),
2.11 (s, 3H), 2.02 (s, 6H), 2.01 (s, 3H), 1.98 (s, 3H) ppm. 13C NMR
(100MHz, acetone-d6): d 170.7 (C), 170.5 (C), 170.4 (C), 170.3 (C),
170.1 (C), 170.1 (C), 138.5 (C), 129.8 (CH), 128.9 (CH), 127.2 (CH),
102.4 (CH), 94.0 (CH), 92.9 (CH), 79.4 (CH), 71.4 (CH), 70.9 (CH),
70.6 (CH), 69.6 (CH), 69.4 (CH), 69.4 (CH), 69.0 (CH2) 64.5 (CH), 62.9
(CH2), 20.7 (CH3), 20.6 (CH3), 20.6 (CH3), 20.6 (CH3) ppm. IR (HATR):
2964 (w), 1741 (s), 1374 (m), 1229 (s), 1214 (s), 1160 (w), 1134 (m),
1062 (m), 1035 (m), 997 (m), 982 (m), 956 (m), 920 (w), 907 (m),
803 (w), 767 (w), 729 (w), 702 (w), 654 (w) cm1. ESMS [m/z (frag-
ment, intensity), positive mode]: 700.2 (MþNH4þ, 100). HRMS
(ESI-TOF): calcd. for C31H42NO17
þ [MþNH4]þ 700.2447;
found 700.2444.
To a suspension of 14 (1 g, 1.465mmol) in MeOH (15ml),
NaOMe (0.950 g, 17.58mmol, 12 eq) was added. The reaction mix-
ture was stirred for 1 h after which silica (1 g) was added. The sus-
pension was filtered and the filtrate was concentrated under
reduced pressure. Purification by flash column chromatography
(eluent CH2Cl2/MeOH 8/2 to 6/4) gave 4,6-O-benzylidene-a,a-D-tre-
halose (13) as a white solid (831mg), but still containing an
impurity according to TLC.
13 (purified sample): Rf 0.60 in acetonitrile/water 8/2. 1H NMR
(400MHz, CD3OD): d 7.51–7.43 (m, 2H), 7.37–7.26 (m, 3H), 5.56 (s,
1H), 5.16 (d, J¼ 4.0 Hz, 1H), 5.08 (d, J¼ 3.8 Hz, 1H), 4.21 (dd,
J¼ 9.8/4.9 Hz, 1H), 4.13–4.03 (m, 1H), 4.00 (t, J¼ 9.4 Hz, 1H),
3.90–3.64 (m, 5H), 3.60 (dd, J¼ 9.4/4.0 Hz, 1H), 3.49 (dd, J¼ 9.8/
3.6 Hz, 1H), 3.47 (t, J¼ 9.6 Hz, 1H), 3.37–3.30 (m, 2H) ppm.
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13C NMR (100MHz, CD3OD): d 139.2 (C), 129.9 (CH), 129.0 (CH),
127.5 (CH), 103.0 (CH), 95.9 (CH), 95.5 (CH), 83.1 (CH), 74.5 (CH),
73.9 (CH), 73.8 (CH), 73.2 (CH), 71.8 (CH), 71.5 (CH), 70.0 (CH2), 64.1
(CH), 62.6 (CH2) ppm. IR (HATR): 3318 (m, br), 2982 (w), 2930 (w),
2868 (w), 1592 (m), 1455 (w), 1375 (m), 1345 (m), 1148 (m), 1122
(m), 1111 (m), 1071 (m), 1047 (m), 1024 (m), 1004 (m), 981 (s), 927
(w), 838 (w), 800 (w), 760 (w), 702 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES negative mode]: 429.1 (M-Hþ, 100). HRMS (ESI-
TOF): calcd. for C19H26NaO11
þ [MþNa]þ 453.1367; found
453.1374. Literature data are available29.
To a solution of crude 13 in anhydrous DMF (12ml), NaH (60%
in mineral oil, 700mg, 17.4mmol) was added slowly (gas forma-
tion). After stirring for 15min, the resulting suspension was cooled
to 0 C and BnBr (1.67ml, 13.9mmol) was added dropwise, fol-
lowed by TBAI (129mg, 0.348mmol). The ice bath was removed
and the reaction mixture was stirred overnight. After cooling to
0 C, MeOH (5ml) was added (gas formation is observed) and the
mixture is stirred for 10min after which it is diluted with ethyl
acetate (40ml). The organic layer was washed with brine
(5 40ml), and dried on MgSO4. The drying agent was filtered
and the filtrate was concentrated under reduced pressure. The
crude product was purified by flash column chromatography (gra-
dient elution: hexane/EtOAc 95/5 to 8/2) giving 11 as a white
solid with a yield of 51% over two steps (725mg, 0.747mmol).
2,3,4,6,2’,3’,6’-Hepta-O-benzyl-a,a-D-trehalose (12)
To a solution of 11 (5.055 g; 5.205mmol) in anhydrous THF
(52ml), molecular sieves (4 Å, 5.00 g) were added. After stirring for
30min, Me3N-BH3 (4.556 g; 62.46mmol, 12 eq) was added. The
resulting mixture was cooled to 0 C and AlCl3 (8.328 g,
65.46mmol, 12 eq) was added. The cooling bath was removed
and the reaction mixture was stirred overnight. The mixture was
diluted with EtOAc (1.6 L) and transferred to a flask containing a
solution of cold 1% aq H2SO4 (800ml, containing ice). After stir-
ring for 30min, the mixture was transferred to a separation funnel,
the organic layer was separated and the aqueous phase was
extracted with EtOAc (3 750ml). The combined organic layers
were washed with saturated NaHCO3 solution (3 2.4 L) and brine
(3 2.4 L). The organic phase was dried on MgSO4, the drying
agent was filtered, and the filtrate was concentrated under
reduced pressure. The residue was purified by flash column chro-
matography (100% toluene, followed by gradient elution: hexane/
EtOAc 9/1 to 75/25), giving the title compound 12 as a colourless
oil (49%, 2.45 g, 2.52mmol). Spectral data were in agreement with
literature30. In addition, the corresponding 6-OH regioisomer
(2,3,4,6,20,30,40-hepta-O-benzyl-a,a-D-trehalose) was isolated (1.90 g,
1.95mmol, 38%). Spectral data were in agreement with
literature31.
2,3,4,6,2’,3’-Hexa-O-benzyl-a,a-D-trehalose (15)
To a solution of 11 (50mg, 0.051mmol) in CH2Cl2/MeOH (1/3,
1.2ml) is added trifluoroacetic acid (0.1ml) and the resulting reac-
tion mixture is stirred for 5 days. The mixture is diluted with
CH3CN and concentrated under reduced pressure. The residue is
purified via column chromatography (gradient elution: hexane/
EtOAc 1/1 to 4/6) to give the title compound 15 as a colourless
glass (34mg, 0.039mmol, 76%).
Rf 0.34 in hexane/EtOAc 4/6. 1H NMR (400MHz, CDCl3): d
7.43–7.20 (m, 28H), 7.18–7.11 (m, 2H), 5.24 (d, J¼ 3.5 Hz, 1H), 5.21
(d, J¼ 3.5 Hz, 1H), 5.03 (d, J¼ 11.5 Hz, 1H), 5.01 (d, J¼ 10.9 Hz, 1H),
4.89 (d, J¼ 10.9 Hz, 1H), 4.84 (d, J¼ 10.7 Hz, 1H), 4.78 (d,
J¼ 11.5Hz, 1H), 4.76–4.63 (m, 4H), 4.55 (d, J¼ 12.1 Hz, 1H), 4.48 (d,
J¼ 10.7 Hz, 1H), 4.39 (d, J¼ 12.1 Hz, 1H), 4.20–4.13 (m, 1H),
4.10–3.98 (m, 2H), 3.89 (app t, J¼ 9.3 Hz, 1H), 3.75–3.47 (m, 7H),
3.40 (dd, J¼ 10.7/1.9 Hz, 1H) ppm. 13C NMR (100MHz, CDCl3): d
138.8 (C), 138.7 (C), 138.3 (C), 138.0 (C), 137.9 (C), 137.8 (C), 128.5
(CH), 128.4 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 128.0 (CH),
127.9 (CH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 127.7 (CH), 127.7
(CH), 127.6 (CH), 127.6 (CH), 127.3 (CH), 94.2 (CH), 94.0 (CH), 81.8
(CH), 80.9 (CH), 79.3 (CH), 79.2 (CH), 77.7 (CH), 75.6 (CH2), 75.2
(CH2), 75.0 (CH2), 73.5 (CH2), 72.9 (CH2), 72.5 (CH2), 71.2 (CH), 70.7
(CH), 70.5 (CH), 68.2 (CH2), 62.2 (CH2) ppm. IR (HATR): 3451 (br, m),
3059 (w), 3030 (w), 2926 (w), 2868 (w), 1496 (w), 1453 (m), 1360
(m), 1326 (w), 1272 (w), 1208 (w), 1153 (m), 1091 (m), 1054 (s),
1026 (m), 991 (s), 918 (w), 849 (w), 799 (w), 733 (s), 695 (s), 638
(w) cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
900.3 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C54H62NO11þ
[MþNH4]þ 900.4317; found 900.4321.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-methyl-a,a-D-tre-
halose (16-a)
General procedure A was applied (use of iodomethane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 8/2) afforded the title compound 16-a as a white
solid (203mg, 0.227mmol, 80%).
Rf 0.27 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.64–7.56 (m, 2H), 7.43–7.26 (m, 10H), 7.24–7.02 (m, 18H), 5.41 (d,
J¼ 3.8 Hz, 1H), 5.39 (s, 1H), 5.33 (d, J¼ 3.7 Hz, 1H), 5.00–4.90 (m,
3H), 4.84–4.63 (m, 5H), 4.58–4.46 (m, 4H), 4.41 (app t, J¼ 9.4 Hz,
1H), 4.36 (app t, J¼ 9.7 Hz, 1H), 4.19 (dd, J¼ 10.1/4.9 Hz, 1H), 3.80
(t, J¼ 10.1/9.2 Hz, 1H), 3.67–3.48 (m, 6H), 3.17 (s, 3H) ppm. 13C
NMR (100MHz, benzene-d6): d 140.2 (C), 140.1 (C), 139.8 (C), 139.3
(C), 139.0 (C), 138.8 (C), 129.3 (CH), 129.1 (CH), 129.0 (CH), 128.9
(CH), 128.8 (CH), 128.7 (CH), 128.3 (CH), 128.2 (CH), 128.2 (CH),
128.0 (CH), 127.8 (CH), 127.1 (CH), 102.0 (CH), 94.8 (CH), 94.0 (CH),
83.4 (CH), 82.7 (CH), 80.7 (CH), 79.7 (CH), 79.7 (CH), 78.9 (CH), 75.8
(CH2), 75.6 (CH2), 75.3 (CH2), 74.2 (CH2), 74.0 (CH2), 72.2 (CH2), 72.1
(CH), 69.7 (CH), 63.8 (CH), 59.4 (CH) ppm. IR (HATR): 3064 (w),
3029 (w), 2923 (w), 2868 (w), 1496 (w), 1453 (m), 1367 (m), 1330
(w), 1208 (w), 1149 (m), 1136 (m), 1085 (s), 1071 (s), 1049 (m),
1027 (m), 985 (s), 915 (w), 854 (w), 797 (w), 734 (m), 695 (s), 658
(w), 633 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 912.3 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C55H62NO11
þ [MþNH4]þ 912.4317; found 912.4343.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-ethyl-a,a-D-tre-
halose (16-b)
General procedure A was applied (use of iodoethane). Purification
via column chromatography (gradient elution: hexane/EtOAc 9/1
to 8/2) afforded the title compound as a white solid (476mg,
0.524mmol, 92%).
Rf 0.32 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.64–7.56 (m, 2H), 7.42–7.27 (m, 10H), 7.23–7.02 (m, 18H), 5.42 (d,
J¼ 3.7 Hz, 1H), 5.38 (s, 1H), 5.33 (d, J¼ 3.5 Hz, 1H), 5.02–4.91 (m,
3H), 4.84–4.66 (m, 5H), 4.58–4.46 (m, 4H), 4.40 (t, J¼ 9.2 Hz, 1H),
4.36 (t, J¼ 9.2 Hz, 1H), 4.18 (dd, J¼ 10.2/4.9 Hz, 1H), 3.86 (t,
J¼ 9.5 Hz, 1H), 3.68–3.49 (m, 6H), 3.45–3.15 (m, 1H), 3.35–3.24 (m,
1H), 1.11 (t, J¼ 7.0 Hz, 3H) ppm. 13C NMR (100MHz, benzene-d6):
d 139.8 (C), 139.7 (C), 139.5 (C), 138.9 (C), 138.6 (C), 138.5 (C),
128.9 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.3
(CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 127.4 (CH),
126.8 (CH), 101.7 (CH), 94.4 (CH), 93.7 (CH), 83.0 (CH), 82.4 (CH),
80.3 (CH), 79.3 (CH), 78.5 (CH), 75.5 (CH2), 75.2 (CH2), 74.9 (CH2),
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73.8 (CH2), 73.6 (CH2), 71.7 (CH), 69.7 (CH2), 69.3 (CH2), 66.9 (CH2),
63.4 (CH), 15.5 (CH3) ppm. IR (HATR): 3064 (w), 3029 (w), 2973 (w),
2914 (w), 2862 (w), 1496 (w), 1454 (m), 1368 (m), 1328 (w), 1209
(w), 1135 (m), 1086 (s), 1071 (s), 984 (s), 915 (m), 797 (w), 734 (m),
695 (s), 659 (w) cm1. ESMS [m/z (fragment, intensity), API-ES posi-
tive mode]: 926.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C56H64NO11
þ [MþNH4]þ 926.4474; found 926.4485.
6-O-Allyl-2,3,4,2’,3’-penta-O-benzyl-4’,6’-O-benzylidene-a,a-D-tre-
halose (16-c)
General procedure A was applied (use of allyl bromide).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 8/2) afforded the title compound 16-c as a white
solid (460mg, 0.499mmol, 88%).
Rf 0.34 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.62–7.57 (m, 2H), 7.41–7.26 (m, 10H), 7.23–7.02 (m, 18H), 5.84
(app ddt, J¼ 17.2/10.4/5.3 Hz, 1H), 5.41 (d, J¼ 3.8 Hz, 1H), 5.38 (s,
1H), 5.33 (d, J¼ 3.5 Hz, 1H), 5.25 (app dq, J¼ 17.3/1.8 Hz, 1H), 5.04
(app dq, J¼ 10.4/1.5 Hz, 1H), 5.00–4.91 (m, 3H), 4.83–4.65 (m, 5H),
4.58–4.47 (m, 4H), 4.40 (app t, J¼ 9.2 Hz, 1H), 4.36 (app t,
J¼ 9.3 Hz, 1H), 4.19 (dd, J¼ 10.1/4.9 Hz, 1H), 3.91 (app ddt,
J¼ 13.1/5.3/1.5 Hz, 1H), 3.88–3.80 (m, 2H), 3.68–3.49 (m, 6H) ppm.
13C NMR (100MHz, benzene-d6): d 139.8 (C), 139.7 (C), 139.4 (C),
138.9 (C), 138.6 (C), 138.5 (C), 135.5 (CH), 128.9 (CH), 128.7 (CH),
128.6 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.8
(CH), 127.6 (CH), 127.4 (CH), 126.8 (CH), 116.3 (CH2), 101.7 (CH),
94.4 (CH), 93.6 (CH), 83.0 (CH), 82.4 (CH), 80.3 (CH), 79.3 (CH), 79.3
(CH), 78.5 (CH), 75.5 (CH2), 75.2 (CH2), 75.0 (CH2), 73.9 (CH2), 73.6
(CH2), 72.5 (CH2), 71.7 (CH), 69.4 (CH2), 63.4 (CH) ppm. IR (HATR):
3064 (w), 3029 (w), 2923 (w), 2864 (w), 1496 (w), 1453 (m), 1366
(m), 1331 (w), 1209 (w), 1151 (m), 1135 (m), 1086 (s), 1071 (s), 985
(s), 928 (m), 734 (m), 695 (s), 656 (m) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 938.4 (MþNH4þ, 100). HRMS





General procedure A was applied (use of 1-iodobutane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 7/3) afforded the title compound 16-d as a white
solid (445mg, 0.475mmol, 84%).
Rf 0.54 in hexane/EtOAc 6/4. 1H NMR (400MHz, benzene-d6): d
7.64–7.56 (m, 2H), 7.43–7.27 (m, 10H), 7.23–7.02 (m, 18H), 5.43 (d,
J¼ 3.8 Hz, 1H), 5.38 (s, 1H), 5.34 (d, J¼ 3.5 Hz, 1H), 5.02 (d,
J¼ 11.4Hz, 1H), 4.95 (d, J¼ 11.6 Hz, 1H), 4.94 (d, J¼ 11.4 Hz, 1H),
4.84–4.66 (m, 5H), 4.58–4.46 (m, 4H), 4.45–4.33 (m, 2H), 4.20 (dd,
J¼ 10.1/4.9 Hz, 1H), 3.95–3.85 (m, 1H), 3.72–3.48 (m, 6H), 3.46–3.38
(m, 1H), 3.35–3.26 (m, 1H), 1.63–1.27 (m, 4H), 0.85 (t, J¼ 7.3 Hz,
3H) ppm. 13C NMR (100MHz, benzene-d6): d 139.8 (C), 139.7 (C),
139.5 (C), 138.9 (C), 138.6 (C), 138.5 (C), 128.9 (CH), 128.7 (CH),
128.6 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.9
(CH), 127.9 (CH), 127.6 (CH), 127.4 (CH), 126.8 (CH), 101.7 (CH),
94.4 (CH), 93.7 (CH), 83.0 (CH), 82.4 (CH), 80.4 (CH), 79.4 (CH), 79.3
(CH), 78.6 (CH), 75.5 (CH2), 75.2 (CH2), 75.0 (CH2), 73.9 (CH2), 73.6
(CH2), 71.7 (CH), 71.5 (CH2), 70.0 (CH2), 69.3 (CH2), 63.4 (CH), 32.3
(CH2), 19.8 (CH2), 14.1 (CH3) ppm. IR (HATR): 3064 (w), 3027 (w),
2932 (w), 2862 (w), 1496 (w), 1454 (m), 1367 (m), 1328 (w), 1210
(w), 1154 (m), 1086 (s), 1072 (s), 985 (s), 915 (m), 733 (m), 695 (s),
657 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 954.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C58H68NO11
þ [MþNH4]þ 954.4787; found 954.4778.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-(2-methylallyl)-
a,a-D-trehalose (16-e)
General procedure A was applied (use of 3-bromo-2-methylpro-
pene, “methallyl bromide”). Purification via column chromatog-
raphy (gradient elution: hexane/EtOAc 9/1 to 8/2) afforded the
title compound 16-e as a white solid (247mg, 0.264mmol, 93%).
Rf 0.64 in hexane/EtOAc 1/1. 1H NMR (400MHz, benzene-d6): d
7.63–7.57 (m, 2H), 7.45–7.26 (m, 10H), 7.24–7.02 (m, 18H), 5.41 (d,
J¼ 3.7 Hz, 1H), 5.38 (s, 1H), 5.33 (d, J¼ 3.5 Hz, 1H), 5.11–5.05 (m,
1H), 5.03–4.90 (m, 3H), 4.89–4.84 (m, 1H), 4.57–4.46 (m, 4H), 4.40
(app t, J¼ 9.3 Hz, 1H), 4.36 (app t, J¼ 9.3 Hz, 1H), 4.19 (dd,
J¼ 10.1/4.9 Hz, 1H), 3.91–3.74 (m, 3H), 3.70–3.47 (m, 6H), 1.67 (s,
3H) ppm. 13C NMR (100MHz, benzene-d6): d 142.7 (C), 139.7 (C),
139.7 (C), 139.4 (C), 138.9 (C), 138.6 (C), 138.5 (C), 128.9 (CH), 128.7
(CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 128.0 (CH),
127.9 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 127.4 (CH), 126.7
(CH), 112.0 (CH2), 101.6 (CH), 94.3 (CH), 93.6 (CH), 83.0 (CH), 82.4
(CH), 80.4 (CH), 79.3 (CH), 79.3 (CH), 78.6 (CH), 75.5 (CH2), 75.5
(CH2), 75.2 (CH2), 75.0 (CH2), 73.9 (CH2), 73.6 (CH2), 71.7 (CH), 69.3
(CH2), 63.4 (CH), 19.6 (CH3) ppm. IR (HATR): 3088 (w), 3060 (w),
3030 (w), 2925 (w), 2861 (w), 1496 (w), 1453 (w), 1388 (w), 1367
(w), 1329 (w), 1279 (w), 1237 (w), 1209 (w), 1153 (m), 1136 (m),
1086 (s), 1072 (s), 1025 (s), 986 (s), 908 (w), 877 (w), 846 (w), 796
(w), 745 (m), 734 (m), 695 (s), 656 (w), 634 (w) cm1. ESMS [m/z
(fragment, intensity), API-ES positive mode]: 952.4 (MþNH4þ,





General procedure A was applied (use of 1-bromo-3-methyl-2-
butene, “prenyl bromide”). Purification via column chromatog-
raphy (hexane/EtOAc 8/2) afforded the partially purified title com-
pound 16-f as a white solid which was used as such in the
next step.
Rf 0.58 in hexane/EtOAc 6/4.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-n-decyl-a,a-D-tre-
halose (16-g)
General procedure A was applied (use of 1-bromodecane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 8/2) afforded the partially purified title compound
16-g as a white solid (320mg), which was used as such in the
next step.
Rf 0.67 in hexane/EtOAc 1/1. ESMS [m/z (fragment, intensity),
API-ES positive mode]: 1038.5 (MþNH4þ, 100). HRMS (ESI-TOF):
calcd. for C64H80NO11
þ [MþNH4]þ 1038.5726; found 1038.5742.
6-O-Methyl-a,a-D-trehalose (17-a)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 17-a as a white solid (77.9mg, 0.219mmol, 96%).
Rf 0.35 in CH2Cl2/MeOH 6/4.
1H NMR (400MHz, CD3OD): d 5.09
(d, J¼ 3.4 Hz, 1H), 5.08 (d, J¼ 3.5 Hz, 1H), 3.94 (ddd, J¼ 10.0/4.9/
2.6 Hz, 1H), 3.85–3.73 (m, 3H), 3.70–3.53 (m, 5H), 3.48 (d, J¼ 3.8 Hz,
1H), 3.45 (d, J¼ 3.8 Hz, 1H), 3.37 (s, 3H), 3.35–3.27 (m, 2H) ppm.
13C NMR (100MHz, CD3OD): d 95.2 (CH), 74.6 (CH), 74.5 (CH), 73.8
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(CH), 73.2 (CH), 73.1 (CH), 73.1 (CH2), 72.4 (CH), 72.0 (CH), 71.9
(CH), 62.6 (CH2), 59.5 (CH3) ppm. IR (HATR): 3292 (br, m), 2927 (w),
1652 (w), 1637 (w), 1455 (w), 1438 (w), 1419 (w), 1363 (w), 1337
(w), 1265 (w), 1197 (w), 1146 (m), 1100 (m), 1079 (m), 1032 (m),
986 (s), 943 (m), 912 (w), 852 (w), 805 (w), 705 (w), 667 (w), 608
(w) cm1. [a]D
22 þ198 (c 0.12, MeOH). ESMS [m/z (fragment,
intensity), API-ES positive mode]: 374.1 (MþNH4þ, 100). HRMS




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 17-b as a white solid (71.9mg, 0.194mmol, 98%).
Rf 0.29 in CH3CN/H2O 8/2, 0.41 in CH2Cl2/MeOH 6/4.
1H NMR
(400MHz, CD3OD): d 5.09 (d, J¼ 3.4 Hz, 1H), 5.08 (d, J¼ 3.5 Hz, 1H),
3.92 (ddd, J¼ 9.9/5.2/2.1 Hz, 1H), 3.85–3.72 (m, 4H), 3.72–3.41 (m,
7H), 3.38–3.28 (m, 2H), 1.18 (t, J¼ 7.0 Hz, 3H) ppm. 13C NMR
(100MHz, CD3OD): d 95.1 (CH), 95.0 (CH), 74.6 (CH), 74.5 (CH), 73.8
(CH), 73.2 (CH), 73.0 (CH), 72.5 (CH), 72.1 (CH), 71.9 (CH), 70.9
(CH2), 67.9 (CH2), 62.6 (CH2), 15.4 (CH3) ppm. IR (HATR): 3305 (br,
m), 2976 (w), 2926 (w), 1652 (w), 1455 (w), 1418 (w), 1375 (w),
1360 (w), 1335 (w), 1271 (w), 1206 (w), 1146 (m), 1100 (m), 1075
(m), 1028 (m), 985 (s), 941 (m), 913 (w), 853 (w), 804 (w), 734 (w),
702 (w), 642 (w), 611 (w) cm1. [a]D
22 þ213 (c 0.14, MeOH). ESMS
[m/z (fragment, intensity), API-ES positive mode]: 388.0 (MþNH4þ,




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 65/35) afforded
the title compound as a white solid (125mg, 0.338mmol, 71%).
Rf 0.34 in CH3CN/H2O 8/2, 0.27 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.09 (d, J¼ 3.3 Hz, 1H), 5.09 (d, J¼ 3.5 Hz, 1H),
3.91 (ddd, J¼ 10.0/5.2/2.1 Hz, 1H), 3.87–3.73 (m, 4H), 3.71–3.56 (m,
3H), 3.54–3.37 (m, 4H), 3.37–3.27 (m, 2H), 1.58 (app hexaplet,
J¼ 7.1 Hz, 2H), 0.92 (t, J¼ 7.4 Hz, 3H), ppm. 13C NMR (100MHz,
CD3OD): d 95.1 (CH), 95.0 (CH), 74.6 (CH), 74.5 (CH), 74.3 (CH2),
73.8 (CH), 73.2 (CH), 73.2 (CH), 72.6 (CH), 72.1 (CH), 71.9 (CH), 71.1
(CH2), 62.6 (CH2), 23.8 (CH2), 10.8 (CH3) ppm. IR (HATR): 3312 (m,
br), 2928 (w), 2872 (w), 1435 (w), 1372 (w), 1334 (w), 1266 (w),
1204 (w), 1146 (m), 1101 (m), 1075 (m), 1033 (m), 987 (s), 943 (m),
912 (w), 853 (w), 845 (w), 804 (w), 700 (w) cm1. [a]D
22 þ231 (c
0.10, MeOH). ESMS [m/z (fragment, intensity), API-ES negative
mode]: 402.2 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C15H28NaO11 [MþNa]þ 407.1524; found 407.1513.
6-O-n-Butyl-a,a-D-trehalose (17-d)
General procedure C was applied. Purification via column chroma-
tography (CH2Cl2/MeOH 7/3) afforded the title compound 17-d as
a white solid (145mg, 0.364mmol, 81%).
Rf 0.21 in CH3CN/H2O 8/2, 0.24 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.13–5.06 (m, 2H), 3.92 (ddd, J¼ 9.9/4.9/
2.1 Hz, 1H), 3.86–3.72 (m, 4H), 3.71–3.41 (m, 7H), 3.37–3.27 (m, 2H),
1.62–1.48 (m, 2H), 1.38 (app hexaplet, J¼ 7.5 Hz, 2H), 0.92 (t,
J¼ 7.4 Hz, 3H) ppm. 13C NMR (100MHz, CD3OD): d 95.1 (CH), 95.0
(CH), 74.6 (CH), 74.5 (CH), 73.8 (CH), 73.2 (CH), 73.2 (CH), 72.6 (CH),
72.4 (CH2), 72.1 (CH), 71.9 (CH), 71.2 (CH2), 62.6 (CH2), 32.8 (CH2),
20.3 (CH2), 14.3 (CH) ppm. IR (HATR): 3301 (m, br), 2929 (w), 2872
(w), 1644 (w), 1455 (w), 1430 (w), 1372 (w), 1334 (w), 1263 (w),
1146 (m), 1101 (m), 1077 (m), 1029 (m), 985 (s), 941 (m), 912 (w),
844 (w), 805 (w), 706 (w) cm1. [a]D
22 þ271 (c 0.12, MeOH). ESMS
[m/z (fragment, intensity), API-ES positive mode]: 416.2 (MþNH4þ,




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound as a white solid (71.0mg, 0.178mmol, 79%).
Rf 0.32 in CH2Cl2/MeOH 6/4.
1H NMR (400MHz, CD3OD): d 5.09
(app d, J¼ 3.7 Hz, 2H), 3.92 (ddd, J¼ 10.0/5.0/2.4 Hz, 1H), 3.84–3.74
(m, 4H), 3.70–3.58 (m, 3H), 3.48 (app t, J¼ 3.8 Hz, 1H), 3.45 (app t,
J¼ 3.8 Hz, 1H), 3.37–3.27 (m, 3H), 3.21 (dd, J¼ 9.3/6.8 Hz, 1H), 1.85
(nonaplet, J¼ 6.7 Hz, 1H), 0.90 (d, J¼ 6.7 Hz, 3H), 0.90 (d, J¼ 6.7 Hz,
3H) ppm. 13C NMR (100MHz, CD3OD): d 95.0 (CH), 94.9 (CH), 79.5
(CH2), 74.7 (CH), 74.6 (CH), 73.8 (CH), 73.2 (CH), 73.2 (CH), 72.6
(CH), 72.1 (CH), 71.9 (CH), 71.3 (CH2), 62.6 (CH2), 29.5 (CH), 19.7
(CH3) ppm. IR (HATR): 3306 (br, m), 2953 (w), 2928 (w), 2875 (w),
1652 (w), 1637 (w), 1456 (w), 1436 (w), 1419 (w), 1388 (w), 1365
(w), 1335 (w), 1270 (w), 1209 (w), 1147 (m), 1102 (m), 1077 (m),
1031 (m), 985 (s), 941 (m), 913 (w), 846 (w), 804 (w), 706 (w), 642
(w), 612 (w) cm1. [a]D
22 þ165 (c 0.10, MeOH). ESMS [m/z (frag-
ment, intensity), API-ES negative mode]: 416.2 (MþNH4þ, 100).




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 17-f as a white solid (40mg, 0.097mmol, 17%
over 2 steps).
Rf 0.29 in CH3CN/H2O 8/2, 0.49 in CH2Cl2/MeOH 6/4.
1H NMR
(400MHz, CD3OD): d 5.10 (d, J¼ 3.3 Hz, 1H), 5.09 (d, J¼ 3.3 Hz, 1H),
3.91 (ddd, J¼ 9.9/4.9/2.2 Hz, 1H), 3.85–3.73 (m, 4H), 3.71–3.41 (m,
7H), 3.38–3.26 (m, 2H), 1.70 (heptaplet, J¼ 6.7 Hz, 1H), 1.46 (q,
J¼ 6.8 Hz, 2H), 0.91 (d, J¼ 6.6 Hz, 6H) ppm. 13C NMR (100MHz,
CD3OD): d 95.1 (CH), 95.0 (CH), 74.6 (CH), 74.5 (CH), 73.8 (CH), 73.2
(CH), 73.1 (CH), 72.6 (CH), 72.1 (CH), 71.9 (CH), 71.2 (CH2), 71.1
(CH2), 62.6 (CH2), 39.6 (CH2), 26.2 (CH), 23.1 (CH3), 23.0 (CH3) ppm.
IR (HATR): 3308 (m, br), 2951 (w), 2926 (w), 2867 (w), 1455 (w),
1423 (w), 1366 (w), 1337 (w), 1266 (w), 1204 (w), 1145 (m), 1102
(m), 1076 (m), 1032 (m), 987 (s), 942 (m), 914 (w), 847 (w), 806 (w)
cm1. [a]D
22 þ183 (c 0.06, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES negative mode]: 430.2 (MþNH4þ, 100). HRMS (ESI-
TOF): calcd. for C17H32NaO11 [MþNa]þ 435.1837; found 435.1833.
6-O-n-Decyl-a,a-D-trehalose (17-g)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 17-g as a white solid (88.0mg, 0.182mmol, 64%
over two steps).
Rf 0.61 in CH2Cl2/MeOH 6/4.
1H NMR (400MHz, CD3OD): d 5.10
(d, J¼ 3.2 Hz, 1H), 5.09 (d, J¼ 3.3 Hz, 1H), 3.92 (ddd, J¼ 10.0/5.1/
2.2 Hz, 1H), 3.85–3.74 (m, 4H), 3.70–3.58 (m, 3H), 3.56–3.41 (m, 4H),
3.37–3.29 (m, 1H), 1.56 (quintet, J¼ 6.9 Hz, 2H), 1.42–1.20 (m, 14H),
0.89 (t, J¼ 6.9 Hz, 3H) ppm. 13C NMR (100MHz, CD3OD): d 95.0
(CH), 94.9 (CH), 79.5 (CH2), 74.6 (CH), 74.5 (CH), 73.8 (CH), 73.2
(CH), 73.1 (CH), 72.8 (CH), 72.6 (CH), 72.1 (CH), 71.9 (CH), 71.1
(CH2), 62.6 (CH2), 33.1 (CH2), 30.7 (CH2), 30.7 (CH2), 30.6 (CH2), 30.5
(CH2), 27.2 (CH2), 23.7 (CH2), 14.4 (CH3) ppm. IR (HATR): 3310 (m,
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br), 2923 (m), 2854 (m), 1456 (w), 1428 (w), 1377 (w), 1337 (w),
1275 (w), 1202 (w), 1146 (m), 1104 (m), 1078 (m), 1034 (m), 987
(s), 941 (m), 912 (w), 848 (w), 805 (w), 720 (w), 708 (w) cm1.
[a]D
22 þ182 (c 0.10, MeOH). ESMS [m/z (fragment, intensity), API-
ES positive mode]: 500.3 (MþNH4þ, 100). HRMS (ESI-TOF): calcd.
for C22H42NaO11
þ [MþNa]þ 505.2619; found 505.2616.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-(N-n-propylcar-
bamoyl)-a,a-D-trehalose (18-a)
General procedure B was applied (use of n-propyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 7/3) afforded the title compound 18-a as a white
foam (187mg, 0.194mmol, 85%).
Rf 0.55 in hexane/EtOAc 1/1. 1H NMR (400MHz, benzene-d6): d
7.63–7.00 (m, 30H), 5.38 (s, 1H), 5.34 (d, J¼ 4.0 Hz, 1H), 5.31 (d,
J¼ 3.3 Hz, 1H), 5.03–4.90 (m, 3H), 4.81–4.03 (m, 16H), 3.79–3.44 (m,
5H), 3.12 (s, 1H), 2.88 (q, J¼ 6.6 Hz, 2H), 1.12 (app sextet,
J¼ 7.3 Hz, 2H), 0.59 (t, J¼ 7.4 Hz, 3H) ppm. 13C NMR (100MHz,
benzene-d6): d 156.2 (C), 139.6 (C), 138.9 (C), 138.7 (C), 138.43 (C),
138.4 (C), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.5 (CH), 128.5 (CH),
128.4 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.9 (CH), 127.8
(CH), 127.5 (CH), 126.7 (CH), 102.8 (CH), 101.7 (CH), 94.6 (CH), 93.6
(CH), 82.9 (CH), 82.3 (CH), 80.1 (CH), 79.4 (CH), 79.2 (CH), 78.2 (CH),
75.5 (CH2), 75.3 (CH2), 75.0 (CH2), 74.1 (CH2), 73.5 (CH2), 70.3 (CH),
69.3 (CH2), 63.5 (CH2), 63.5 (CH2), 51.9 (CH), 42.9 (CH2), 23.3 (CH2),
11.1 (CH3) ppm. IR (HATR): 3060 (w), 3031 (w), 2932 (w), 2869 (w),
1722 (m), 1517 (w), 1496 (w), 1454 (m), 1388 (w), 1368 (s), 1330
(w), 1279 (w), 1259 (w), 1234 (w), 1212 (w), 1153 (m), 1134 (m),
1085 (s), 1072 (s), 1005 (s), 981 (s), 930 (m), 874 (w), 846 (w), 798
(w), 747 (m), 734 (m), 695 (s), 654 (w), 631 (w) cm1. ESMS [m/z
(fragment, intensity), API-ES positive mode]: 983.4 (MþNH4þ,





General procedure B was applied (use of isopropyl isocyanate).
Purification via column chromatography (hexane/EtOAc 8/2)
afforded the title compound 18-b as a white foam (174mg,
0.180mmol, 79%).
Rf 0.64 in hexane/EtOAc 1/1. 1H NMR (400MHz, benzene-d6): d
7.63–7.58 (m, 2H), 7.38–7.27 (m, 10H), 7.25–6.92 (m, 38H), 5.38 (s,
1H), 5.35 (d, J¼ 3.8 Hz, 1H), 5.32 (d, J¼ 3.5 Hz, 1H), 5.00–4.92 (m,
3H), 4.80–4.62 (m, 4H), 4.62–4.31 (m, 9H), 4.19 (dd, J¼ 10.1/4.9 Hz,
1H), 4.11–4.00 (m, 1H), 3.81–3.43 (m, 6H), 0.79 (d, J¼ 6.6 Hz, 3H),
0.76 (d, J¼ 6.6 Hz, 3H) ppm. 13C NMR (100MHz, benzene-d6): d
153.4 (C), 139.6 (C), 138.9 (C), 138.7 (C), 138.4 (C), 128.9 (CH), 128.8
(CH), 128.8 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 128.4 (CH),
128.3 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.5 (CH), 127.5
(CH), 126.7 (CH), 101.6 (CH), 94.6 (CH), 93.6 (CH), 82.9 (CH), 82.3
(CH), 80.2 (CH), 79.4 (CH), 79.2 (CH), 78.2 (CH), 75.5 (CH2), 75.2
(CH2), 75.0 (CH2), 74.1 (CH2), 73.5 (CH2), 70.3 (CH), 69.3 (CH2), 63.5
(CH), 63.4 (CH2), 43.0 (CH), 22.7 (CH3), 22.6 (CH3) ppm. IR (HATR):
3060 (w), 3031 (w), 2970 (w), 2932 (w), 2868 (w), 1718 (m), 1505
(w), 1497 (w), 1454 (m), 1385 (w), 1367 (w), 1321 (w), 1234 (w),
1212 (w), 1153 (w), 1134 (m), 1086 (s), 1071 (s), 1025 (m), 984 (s),
913 (w), 874 (m), 846 (w), 798 (w), 748 (m), 734 (m), 695 (s), 656
(w), 631 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 983.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C58H67N2O12
þ [MþNH4]þ 983.4689; found 983.4666.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-(N-cyclohexylcar-
bamoyl)-a,a-D-trehalose (18-c)
General procedure B was applied (use of cyclohexyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 7/3) afforded the title compound 18-c as a white
foam (411mg, 0.408mmol, 81%).
Rf 0.29 in hexane/EtOAc 6/4. 1H NMR (400MHz, benzene-d6): d
7.63–7.58 (m, 2H), 7.39–7.28 (m, 10H), 7.23–7.02 (m, 18H), 5.39 (s,
1H), 5.36 (d, J¼ 3.7 Hz,1H), 5.33 (d, J¼ 3.4 Hz, 1H), 5.01–4.92 (m,
3H), 4.79–4.69 (m, 4H), 4.66–4.45 (m, 7H), 4.40 (app t, J¼ 9.3 Hz,
1H), 4.37 (app t, J¼ 9.3 Hz, 1H), 4.26–4.18 (m, 1H), 4.20 (dd, J¼ 10.
2/4.8 Hz, 1H), 3.75 (app br t, J¼ 9.2 Hz, 1H), 3.70–3.47 (m, 5H), 1.75
(app br t, J¼ 12.8 Hz, 2H), 1.44–1.24 (m, 3H), 1.10–0.70 (m, 5H)
ppm. 13C NMR (100MHz, benzene-d6): d 155.4 (C), 139.6 (C), 138.9
(C), 138.7 (C), 138.4 (C), 138.4 (C), 128.9 (CH), 128.8 (CH), 128.7
(CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 127.9 (CH), 127.8 (CH),
127.5 (CH), 127.5 (CH), 126.7 (CH), 101.7 (CH), 94.6 (CH), 93.6 (CH),
82.9 (CH), 82.3 (CH), 80.2 (CH), 79.4 (CH), 79.2 (CH), 78.2 (CH), 75.5
(CH2), 75.3 (CH2), 75.1 (CH2), 74.1 (CH2), 73.5 (CH2), 70.4 (CH), 69.3
(CH2), 63.5 (CH), 49.9 (CH), 33.4 (CH2), 33.3 (CH2), 25.7 (CH2), 24.9
(CH2) ppm. IR (HATR): 3032 (w), 2930 (w), 2854 (w), 1719 (m), 1496
(m), 1453 (m), 1365 (w), 1331 (w), 1315 (w), 1272 (w), 1251 (w),
1211 (m), 1151 (m), 1086 (s), 1072 (s), 985 (s), 735 (m), 696 (s), 658
(w) cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
1023.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C61H71N2O12þ
[MþNH4]þ 1023.5002; found 1023.5013.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-(N-phenylcarba-
moyl)-a,a-D-trehalose (18-d)
General procedure B was applied (use of phenyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 7/3) afforded the title compound 18-d as a white
foam (184mg, 0.185mmol, 81%).
Rf 0.25 in hexane/EtOAc 8/2. 1H NMR (400MHz, benzene-d6): d
7.64–7.58 (m, 2H), 7.39–7.25 (m, 12H), 7.24–6.98 (m, 20H), 6.82 (tt,
J¼ 7.4/1.1 Hz, 1H), 6.14 (s, 1H), 5.39 (s, 1H), 5.33 (d, J¼ 3.8 Hz, 1H),
5.31 (d, J¼ 3.6 Hz, 1H), 5.02–4.88 (m, 3H), 4.82–4.63 (m, 4H),
4.60–4.32 (m, 9H), 4.21 (dd, J¼ 10.1/4.9 Hz, 1H), 3.77–3.45 (m, 5H)
ppm. 13C NMR (100MHz, benzene-d6): d 153.1 (C), 139.6 (C), 139.5
(C), 138.8 (C), 138.7 (C), 138.6 (C), 138.4 (C), 138.4 (C), 129.1 (CH),
129.0 (CH), 128.8 (CH), 128.7 (CH), 128.5 (CH), 128.5 (CH), 128.5
(CH), 128.4 (CH), 128.3 (CH), 128.0 (CH), 128.0 (CH), 128.0 (CH),
127.9 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 127.5 (CH), 126.7
(CH), 123.3 (CH), 118.6 (CH), 101.7 (CH), 94.8 (CH), 93.7 (CH), 82.9
(CH), 82.3 (CH), 80.1 (CH), 79.4 (CH), 79.2 (CH), 77.6 (CH), 75.5
(CH2), 75.3 (CH2), 74.9 (CH2), 74.2 (CH2), 73.4 (CH2), 70.0 (CH), 69.3
(CH2), 63.8 (CH2), 63.5 (CH) ppm. IR (HATR): 3391 (w), 3318 (w),
3060 (w), 3031 (w), 2931 (w), 2866 (w), 1732 (m), 1715 (m), 1601
(w), 1525 (m), 1497 (w), 1454 (m), 1444 (m), 1385 (w), 1367 (w),
1313 (w), 1210 (m), 1156 (w), 1137 (w), 1086 (s), 1071 (s), 985 (s),
912 (w), 877 (w), 846 (w), 798 (w), 748 (m), 734 (m), 694 (s), 656
(w) cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
1017.3 (MþNHþ, 100). HRMS (ESI-TOF): calcd. for C61H65N2O12þ
[MþNH4]þ 1017.4532; found 1017.4524.
2,3,4,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-6-O-(N-benzylcarba-
moyl)-a,a-D-trehalose (18-e)
General procedure B was applied (use of benzyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 6/4) afforded the title compound 18-e as a white
foam (457mg, 0.451mmol, 79%).
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Rf 0.27 in hexane/EtOAc 6/4. 1H NMR (400MHz, benzene-d6): d
7.64–7.57 (m, 2H), 7.39–7.27 (m, 10H), 7.24–6.94 (m, 23H), 5.39 (s,
1H), 5.33 (br d, J¼ 3.4 Hz, 1H), 5.31 (br d, J¼ 2.9 Hz, 1H), 5.02–4.87
(m, 3H), 4.80–4.30 (m, 14H), 4.21 (dd, J¼ 10.1/4.9 Hz, 1H),
4.15–4.01 (m, 2H), 3.76–3.49 (m, 5H) ppm. 13C NMR (100MHz, ben-
zene-d6): d 156.3 (C), 139.6 (C), 138.9 (C), 138.6 (C), 138.4 (C), 128.9
(CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 128.5 (CH),
128.4 (CH), 128.1 (CH), 127.9 (CH), 127.5 (CH), 127.5 (CH), 127.4
(CH), 126.7 (CH), 101.7 (CH), 94.6 (CH), 93.6 (CH), 82.9 (CH), 82.2
(CH), 80.1 (CH), 79.4 (CH), 79.3 (CH), 78.1 (CH), 75.5 (CH2), 75.3
(CH2), 75.0 (CH2), 74.1 (CH2), 73.4 (CH2), 70.2 (CH), 69.3 (CH2), 63.7
(CH2), 63.5 (CH), 45.2 (CH2) ppm. IR (HATR): 3064 (w), 3030 (w),
2923 (w), 2871 (w), 1723 (m), 1513 (w), 1496 (m), 1453 (m), 1366
(m), 1331 (w), 1235 (m), 1210 (m), 1154 (m), 1138 (m), 1086 (s),
1073 (s), 985 (s), 915 (w), 735 (m), 696 (s), 652 (w) cm1. ESMS [m/
z (fragment, intensity), API-ES positive mode]: 1031.4 (MþNH4þ,





General procedure B was applied (use of phenethyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 7/3) afforded the title compound 18-f as a white
foam (220mg, 0.214mmol, 94%).
Rf 0.13 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.64–7.57 (m, 2H), 7.40–7.27 (m, 10H), 7.26–6.85 (m, 23H), 5.39 (s,
1H), 5.34 (d, J¼ 3.8 Hz, 1H), 5.31 (d, J¼ 3.5 Hz, 1H), 4.97 (d,
J¼ 11.6Hz, 1H), 4.95 (d, J¼ 11.2 Hz, 1H), 4.93 (d, J¼ 11.0 Hz, 1H),
4.80–4.10 (m, 15H), 3.77–3.47 (m, 5H), 3.26–3.07 (m, 2H), 2.53–2.38
(m, 2H) ppm. 13C NMR (100MHz, benzene-d6): d 156.1 (C), 139.6
(C), 139.3 (C), 138.9 (C), 138.6 (C), 138.4 (C), 138.4 (C), 129.0 (CH),
128.9 (CH), 128.8 (CH), 128.7 (CH), 128.7 (CH), 128.5 (CH), 128.5
(CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 128.0 (CH), 128.0 (CH),
128.0 (CH), 127.8 (CH), 127.5 (CH), 127.5 (CH), 126.7 (CH), 126.6
(CH), 101.7 (CH), 94.6 (CH), 93.6 (CH), 82.9 (CH), 82.3 (CH), 80.1
(CH), 79.4 (CH), 79.3 (CH), 78.1 (CH), 75.5 (CH2), 75.3 (CH2), 75.0
(CH2), 74.1 (CH2), 73.4 (CH2), 70.3 (CH), 69.3 (CH2), 63.5 (CH2), 63.5
(CH), 42.5 (CH2), 36.3 (CH2) ppm. IR (HATR): 3420 (w), 3060 (w),
3030 (w), 2932 (w), 2866 (w), 1722 (m), 1514 (w), 1496 (w), 1454
(m), 1391 (w), 1367 (w), 1329 (w), 1237 (w), 1210 (w), 1150 (w),
1137 (w), 1086 (s), 1072 (s), 984 (s), 913 (w), 874 (w), 849 (w), 824
(w), 798 (m), 734 (w), 695 (s), 656 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 1045.4 (MþNH4þ, 100). HRMS





General procedure B was applied (use of n-octyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 7/3) afforded the partially purified title compound
18-g as a white foam (494mg), which was used as such in the
next step.
Rf 0.52 in hexane/EtOAc 6/4. HRMS (ESI-TOF): calcd. for
C63H77N2O12
þ [MþNH4]þ 1053.5471; found 1053.5472.
6-O-(N-n-Propylcarbamoyl)-a,a-D-trehalose (19-a)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 19-a as a white solid (64.0mg, 0.150mmol, 93%).
Rf 0.56 in CH3CN/H2O 8/2, 0.11 in CH2Cl2/MeOH 9/1.
1H NMR
(400MHz, CD3OD): d 5.08 (d, J¼ 2.8 Hz, 1H), 5.07 (d, J¼ 3.2 Hz, 1H),
4.25 (dd, J¼ 11.6/1.7 Hz, 1H), 4.19 (dd, J¼ 11.7/4.9 Hz, 1H), 3.98 (br
ddd, J¼ 10.0/2.6/2.0 Hz, 1H), 3.85–3.73 (m, 4H), 3.66 (dd, J¼ 12.0/
5.5 Hz, 1H), 3.55–3.31 (m, 4H), 3.05 (t, J¼ 7.0 Hz, 2H), 1.49 (app sex-
tet, J¼ 7.3 Hz, 2H), 0.90 (t, J¼ 7.4 Hz, 3H) ppm. 13C NMR (100MHz,
CD3OD): d 159.2 (C), 95.2 (CH), 95.1 (CH), 74.6 (CH), 74.4 (CH), 73.9
(CH), 73.2 (CH), 73.2 (CH), 71.9 (CH), 71.8 (CH), 64.8 (CH2), 62.6
(CH2), 43.6 (CH2), 24.1 (CH2), 11.6 (CH3) ppm. IR (HATR): 3304 (br,
m), 2964 (w), 2933 (w), 1684 (m), 1540 (w), 1456 (w), 1419 (w),
1363 (w), 1337 (w), 1265 (m), 1147 (m), 1103 (m), 1076 (m), 1030
(m), 984 (s), 941 (w), 913 (w), 845 (w), 805 (w), 776 (w), 614 (w)
cm1. [a]D
22 þ150 (c 0.10, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES negative mode]: 486.2 (MþOAc-, 100). HRMS (ESI-
TOF): calcd. for C16H30NO12
þ [MþH]þ 428.1763; found 428.1771.
6-O-(N-Isopropylcarbamoyl)-a,a-D-trehalose (19-b)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 19-b as a white solid (207mg, 0.484mmol, 93%).
Rf 0.55 in CH3CN/H2O 8/2, 0.11 in CH2Cl2/MeOH 9/1.
1H NMR
(400MHz, CD3OD): d 5.13–5.02 (m, 2H), 4.40–4.13 (m, 2H), 3.98 (br
d, J¼ 8.9 Hz, 1H), 3.85–3.63 (m, 6H), 3.46 (app dd, J¼ 9.8/3.7 Hz,
2H), 3.37–3.26 (m, 2H), 1.12 (d, J¼ 6.5 Hz, 6H) ppm. 13C NMR
(100MHz, CD3OD): d 158.3 (C), 95.2 (CH), 95.1 (CH), 74.6 (CH), 74.4
(CH), 73.9 (CH), 73.2 (CH), 73.2 (CH), 71.9 (CH), 71.8 (CH), 64.7
(CH2), 62.6 (CH2), 44.0 (CH), 22.9 (CH3) ppm. IR (HATR): 3303 (br,
m), 2970 (w), 2932 (w), 1684 (m), 1540 (w), 1456 (w), 1436 (w),
1419 (w), 1388 (w), 1368 (w), 1349 (w), 1324 (w), 1254 (m), 1147
(w), 1103 (m), 1076 (m), 1042 (m), 1024 (m), 984 (s), 941 (m), 845
(w), 806 (w), 775 (w), 715 (w), 608 (w) cm1. [a]D
22 þ222 (c 0.10,
MeOH). ESMS [m/z (fragment, intensity), API-ES negative mode]:
486.2 (MþOAc, 100). HRMS (ESI-TOF): calcd. for C16H30NO12þ
[MþH]þ 428.1763; found 428.1772.
6-O-(N-Cycloheylcarbamoyl)-a,a-D-trehalose (19-c)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 6/4) afforded the
title compound 19-c as a white solid (170mg, 0.364mmol, 88%).
Rf 0.15 in CH2Cl2/MeOH 8/2.
1H NMR (400MHz, CD3OD): d
5.12–5.03 (m, 2H), 4.40–4.12 (m, 2H), 3.98 (br d, J¼ 9.2 Hz, 1H),
3.85–3.73 (m, 4H), 3.66 (dd, J¼ 12.0/5.6 Hz, 1H), 3.46 (dd, J¼ 9.8/
3.7 Hz, 2H), 3.40–3.26 (m, 3H), 1.86 (app br d, J¼ 11.0 Hz, 2H),
1.80–1.68 (m, 2H), 1.66–1.56 (m, 1H), 1.33 (app qt, J¼ 12.5/3.1 Hz,
2H), 1.25–1.09 (m, 3H), ppm. 13C NMR (100MHz, CD3OD): d 158.3
(C), 95.2 (CH), 95.1 (CH), 74.6 (CH), 74.4 (CH), 73.9 (CH), 73.2 (CH),
73.2 (CH), 71.9 (CH), 71.8 (CH), 64.8 (CH2), 62.6 (CH2), 51.3 (CH),
34.2 (CH2), 26.6 (CH2), 26.2 (CH2) ppm. IR (HATR): 3293 (br, m),
2928 (m), 2858 (w), 1694 (m), 1538 (m), 1453 (m), 1418 (w), 1368
(w), 1317 (m), 1275 (m), 1253 (m), 1237 (m), 1145 (m), 1101 (m),
1076 (m), 1030 (s), 987 (s), 941 (m), 807 (w), 777 (w), 725 (m)
cm1. [a]D
22 þ166 (c 0.10, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES negative mode]: 933.3 (2M-Hþ, 44), 526.2 (MþOAc,
100). HRMS (ESI-TOF): calcd. for C19H33NNaO12
þ [MþNa]þ
490.1895; found 490.1889.
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6-O-(N-Phenylcarbamoyl)-a,a-D-trehalose (19-d)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 19-d as a white solid (41.0mg, 0.089mmol, 57%).
Rf 0.59 in CH3CN/H2O 8/2, 0.15 in CH2Cl2/MeOH 9/1.
1H NMR
(400MHz, CD3OD): d 7.41 (d, J¼ 7.9 Hz, 2H), 7.25 (t, J¼ 8.0 Hz, 2H),
7.00 (t, J¼ 7.4 Hz, 1H), 5.12 (app d, J¼ 3.8 Hz, 2H), 4.37 (dd,
J¼ 11.7/1.9 Hz, 1H), 4.31 (dd, J¼ 11.7/4.9 Hz, 1H), 4.06 (ddd,
J¼ 10.0/4.8/2.3 Hz, 1H), 3.87–3.72 (m, 4H), 3.66 (dd, J¼ 11.8/5.3 Hz,
1H), 3.54–3.28 (m, 6H) ppm. 13C NMR (100MHz, CD3OD): d 156.1
(C), 140.1 (C), 129.8 (CH), 124.1 (CH), 119.9 (CH), 95.3 (CH), 95.2
(CH), 74.6 (CH), 74.4 (CH), 73.9 (CH), 73.2 (CH), 73.2 (CH), 71.9 (CH),
71.8 (CH), 71.7 (CH), 65.0 (CH2), 62.6 (CH2) ppm. IR (HATR): 3302
(br, m), 2970 (w), 2932 (w), 1694 (m), 1684 (m), 1540 (w), 1455 (w),
1447 (w), 1419 (w), 1388 (w), 1368 (w), 1322 (w), 1251 (w), 1147
(w), 1100 (m), 1078 (m), 1039 (m), 1025 (m), 985 (s), 941 (w), 844
(w), 806 (w), 774 (w), 751 (w), 720 (w), 695 (w) cm1. [a]D
22 þ152
(c 0.10, MeOH). ESMS [m/z (fragment, intensity), API-ES negative
mode]: 460.2 (M-Hþ, 100). HRMS (ESI-TOF): calcd. for C19H31N2O12
þ
[MþNH4]þ 479.1872; found 479.1867.
6-O-(N-Benzylcarbamoyl)-a,a-D-trehalose (19-e)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 19-e as a white solid (200mg, 0.421mmol, 74%
over 2 steps).
Rf 0.33 in CH3CN/H2O 8/2, 0.09 in CH2Cl2/MeOH 8/2.
1H NMR
(400MHz, CD3OD): d 7.36–7.17 (m, 5H), 5.09 (d, J¼ 3.4 Hz, 1H),
5.07 (d, J¼ 3.4 Hz, 1H), 4.30 (br dd, J¼ 12.0/1.7 Hz, 1H), 4.28 (s,
2H), 4.22 (dd, J¼ 11.7/5.0 Hz, 1H), 4.00 (br ddd, J¼ 9.9/4.8/1.9 Hz,
1H), 3.85–3.72 (m, 4H), 3.66 (dd, J¼ 12.0/5.6 Hz, 1H), 3.51–3.41 (m,
2H), 3.38–3.27 (m, 2H) ppm. 13C NMR (100MHz, CD3OD): d 159.3
(C), 140.6 (C), 129.5 (CH), 128.3 (CH), 128.1 (CH), 95.2 (CH), 95.1
(CH), 74.6 (CH), 74.4 (CH), 73.9 (CH), 73.2 (CH), 73.2 (CH), 71.9 (CH),
71.8 (CH), 65.1 (CH2), 62.6 (CH2), 45.5 (CH2) ppm. IR (HATR): 3311
(m, br), 2930 (w), 1688 (m), 1540 (m), 1454 (w), 1433 (w), 1364 (w),
1338 (w), 1258 (m), 1147 (m), 1102 (m), 1076 (m), 1026 (m), 985
(s), 941 (m), 848 (w), 805 (w), 777 (w), 736 (w), 696 (w), 610 (w)
cm1. [a]D
22 þ140 (c 0.10, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES negative mode]: 949.2 (2M-Hþ, 47), 534.2 (MþOAc-,




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 19-f as a white solid (85.8mg, 0.175mmol, 90%).
Rf 0.47 in CH3CN/H2O 8/2, 0.35 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 7.31–7.13 (m, 5H), 5.08 (d, J¼ 3.9 Hz, 1H),
5.07 (d, J¼ 3.9 Hz, 1H), 4.27 (dd, J¼ 11.7/1.7 Hz, 1H), 4.20 (dd,
J¼ 11.8/4.9 Hz, 1H), 3.98 (ddd, J¼ 9.9/4.5/1.8 Hz, 1H), 3.86–3.73 (m,
4H), 3.67 (dd, J¼ 12.1/5.6 Hz, 1H), 3.51–3.42 (m, 2H), 338–3.24 (m,
4H), 2.77 (t, J¼ 7.4 Hz, 2H) ppm. 13C NMR (100MHz, CD3OD): d
159.1 (C), 140.6 (C), 129.8 (CH), 129.5 (CH), 127.3 (CH), 95.2 (CH),
95.1 (CH), 74.6 (CH), 74.4 (CH), 73.9 (CH), 73.2 (CH), 73.2 (CH), 71.9
(CH), 71.8 (CH), 71.8 (CH), 64.8 (CH2), 62.6 (CH2), 43.5 (CH2), 37.1
(CH2) ppm. IR (HATR): 3306 (br, m), 3026 (w), 2931 (w), 1694 (m),
1540 (w), 1497 (w), 1454 (w), 1436 (w), 1419 (w), 1363 (w), 1332
(w), 1254 (m), 1204 (w), 1147 (m), 1103 (m), 1075 (m), 1047 (m),
1026 (m), 985 (s), 941 (m), 847 (w), 806 (w), 773 (w), 748 (w), 698
(w), 667 (w) cm1. [a]D
22 þ152 (c 0.10, MeOH). ESMS [m/z (frag-
ment, intensity), API-ES negative mode]: 977.3 (2M-Hþ, 60), 548.2
(MþOAc-, 100). HRMS (ESI-TOF): calcd. for C21H32NO12þ [MþH]þ
490.1919; found 490.1922.
6-O-(N-n-Octylcarbamoyl)-a,a-D-trehalose (19-g)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 19-g as a white solid (191mg, 0.179mmol, 84%
over 2 steps).
Rf 0.50 in CH2Cl2/MeOH 6/4.
1H NMR (400MHz, CD3OD): d
5.14–5.03 (m, 2H), 4.30–4.14 (m, 2H), 3.99 (br d, J¼ 7.8 Hz, 1H),
3.87–3.74 (m, 4H), 3.67 (br dd, J¼ 11.8/5.2 Hz, 1H), 3.55–3.43 (m,
2H), 3.39–3.26 (m, 2H), 3.07 (app br t, J¼ 6.7 Hz, 2H), 1.55–1.20 (m,
12H), 0.95–0.83 (m, 3H) ppm. 13C NMR (100MHz, CD3OD): d 159.1
(C), 95.2 (CH), 95.1 (CH), 74.5 (CH), 74.3 (CH), 73.8 (CH), 73.2 (CH),
73.1 (CH), 71.9 (CH), 71.7 (CH), 64.8 (CH2), 62.6 (CH2), 41.8 (CH2),
33.0 (CH2), 30.9 (CH2), 30.4 (CH2), 30.4 (CH2), 27.9 (CH2), 23.7 (CH2),
14.4 (CH3) ppm. IR (HATR): 3314 (m, br), 2924 (m), 2857 (w), 1693
(m), 1539 (m), 1456 (w), 1371 (w), 1334 (w), 1260 (m), 1147 (m),
1106 (m), 1076 (m), 1025 (m), 986 (s), 941 (m), 912 (w), 853 (w),
805 (w), 777 (w) cm1. [a]D
22 þ171 (c 0.10, MeOH). ESMS [m/z
(fragment, intensity), API-ES negative mode]: 993.4 (2M-Hþ, 45),
556.2 (MþOAc-, 100). HRMS (ESI-TOF): calcd. for C21H39NNaO12þ
[MþNa]þ 520.2365; found 520.2355.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-methyl-a,a-D-tre-
halose (20-a)
General procedure A was applied (use of iodomethane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 8/2 containing 1% Et3N) afforded the title compound
20-a as a colourless glass (194mg, 0.217mmol, 95%).
Rf 0.39 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.63–7.56 (m, 2H), 7.39–7.28 (m, 10H), 7.24–7.02 (m, 18H), 5.39 (d,
J¼ 3.8 Hz, 1H), 5.37 (s, 1H), 5.32 (d, J¼ 3.5 Hz, 1H), 4.94 (d,
J¼ 11.6 Hz, 1H), 4.92 (d, J¼ 11.4Hz, 1H), 4.80 (d, J¼ 11.6 Hz, 1H),
4.76 (d, J¼ 11.3Hz, 1H), 4.70 (d, J¼ 11.6Hz, 1H), 4.69 (d,
J¼ 12.1 Hz, 1H), 4.59–4.43 (m, 6H), 4.37 (app t, J¼ 9.3 Hz, 1H), 4.28
(app t, J¼ 9.3 Hz, 1H), 4.18 (dd, J¼ 10.1/4.9 Hz, 1H), 3.72–3.48 (m,
7H), 3.45 (s, 3H) ppm. 13C NMR (100MHz, benzene-d6): d 140.2 (C),
140.1 (C), 139.5 (C), 139.3 (C), 139.1 (C), 138.9 (C), 129.3 (CH), 129.1
(CH), 129.0 (CH), 128.9 (CH), 128.8 (CH), 128.7 (CH), 127.8 (CH),
127.8 (CH), 127.1 (CH), 102.0 (CH), 94.8 (CH), 94.1 (CH), 83.3 (CH),
82.7 (CH), 80.6 (CH), 80.6 (CH), 79.7 (CH), 79.6 (CH), 75.7 (CH2), 75.6
(CH2), 74.1 (CH2), 74.0 (CH2), 74.0 (CH2), 72.1 (CH), 70.0 (CH2), 69.6
(CH2), 63.8 (CH), 60.7 (CH) ppm. IR (HATR): 3032 (w), 2921 (m),
2859 (w), 1728 (w), 1496 (w), 1453 (m), 1369 (m), 1331 (w), 1262
(w), 1208 (w), 1154 (m), 1138 (m), 1086 (s), 1049 (m), 986 (s), 913
(w), 797 (w), 733 (m), 695 (s), 656 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 912.3 (MþNH4þ, 100). HRMS





General procedure A was applied (use of iodoethane). Purification
via column chromatography (gradient elution: hexane/EtOAc 9/1
to 8/2 containing 1% Et3N) afforded the title compound 20-b as a
colourless glass (195mg, 0.215mmol, 83%).
Rf 0.35 in hexane/EtOAc7/3. 1H NMR (400MHz, benzene-d6): d
7.62–7.56 (m, 2H), 7.39–7.27 (m, 10H), 7.23–7.01 (m, 18H), 5.40 (d,
J¼ 3.7 Hz, 1H), 5.37 (s, 1H), 5.32 (d, J¼ 3.7 Hz, 1H), 4.97–4.89 (m,
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2H), 4.81 (d, J¼ 11.4 Hz, 1H), 4.76 (d, J¼ 12.1 Hz, 1H), 4.70 (d,
J¼ 11.6Hz, 1H), 4.68 (d, J¼ 12.1Hz, 1H), 4.61–4.40 (m, 7H), 4.37
(app t, J¼ 9.2 Hz, 1H), 4.28 (app t, J¼ 9.3 Hz, 1H), 4.18 (dd,
J¼ 10.3/4.9 Hz, 1H), 3.94–3.82 (m, 1H), 3.73–3.48 (m, 8H), 1.08 (t,
J¼ 7.0 Hz, 3H) ppm. 13C NMR (100MHz, benzene-d6): d 140.3 (C),
140.2 (C), 139.5 (C), 139.4 (C), 139.1 (C), 138.9 (C), 129.3 (CH), 129.1
(CH), 129.0 (CH), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.3 (CH),
128.3 (CH), 128.1 (CH), 127.8 (CH), 127.1 (CH), 102.0 (CH), 94.8
(CH), 94.1 (CH), 83.3 (CH), 82.7 (CH), 80.6 (CH), 79.7 (CH), 79.6 (CH),
79.0 (CH), 75.8 CH2), 75.6 (CH2), 74.1 (CH2), 74.1 (CH2), 74.0 (CH2),
72.2 (CH), 69.9 (CH2), 68.7 (CH2), 63.8 (CH), 16.5 (CH3) ppm. IR
(HATR): 3064 (w), 3030 (w), 2968 (w), 2923 (w), 2863 (w), 1496 (w),
1453 (m), 1370 (m), 1329 (w), 1208 (w), 1151 (m), 1135 (m), 1085
(s), 1076 (s), 1049 (m), 1013 (m), 984 (s), 915 (w), 877 (w), 796 (w),
733 (m), 695 (s), 656 (w), 632 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 926.4 (MþNH4þ, 100). HRMS





General procedure A was applied (use of allyl bromide).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 75/25 containing 1% Et3N) afforded the title com-
pound 20-c as a colourless glass (179mg, 0.194mmol, 93%).
Rf 0.41 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.63–7.57 (m, 2H), 7.40–7.27 (m, 10H), 7.24–7.01 (m, 18H), 5.85
(app ddt, J¼ 17.2/10.5/5.3 Hz, 1H), 5.39 (d, J¼ 3.7 Hz, 1H), 5.37 (s,
1H), 5.32 (d, J¼ 3.7 Hz, 1H), 5.21 (app dq, J¼ 17.2/1.7 Hz, 1H), 5.01
(app dq, J¼ 10.5/1.4 Hz, 1H), 4.94 (d, J¼ 11.5 Hz, 1H), 4.92 (d,
J¼ 11.1Hz, 1H), 4.79 (d, J¼ 11.2 Hz, 1H), 4.77 (d, J¼ 12.1 Hz, 1H),
4.74–4.64 (m, 2H), 4.59–4.34 (m, 8H), 4.30 (app t, J¼ 9.3 Hz, 1H),
4.18 (dd, J¼ 10.3/4.9 Hz, 1H), 4.14 (app ddt, J¼ 12.9/5.3/1.5 Hz,
1H), 3.78–3.47 (m, 7H) ppm. 13C NMR (100MHz, benzene-d6): d
139.8 (C), 139.7 (C), 139.0 (C), 139.0 (C), 138.7 (C), 138.5 (C), 135.8
(CH), 128.9 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH),
128.0 (CH), 127.9 (CH), 127.9 (CH), 127.9 (CH), 127.8 (CH), 127.7
(CH), 127.4 (CH), 126.8 (CH), 115.7 (CH2), 101.6 (CH), 94.4 (CH), 93.7
(CH), 83.0 (CH), 82.3 (CH), 80.2 (CH), 79.3 (CH), 78.3 (CH), 75.4
(CH2), 75.2 (CH2), 73.8 (CH2), 73.7 (CH2), 73.7 (CH2), 73.6 (CH2), 71.7
(CH), 69.5 (CH2), 69.3 (CH2), 63.4 (CH) ppm. IR (HATR): 3064 (w),
3032 (w), 2927 (w), 2864 (w), 1496 (w), 1453 (m), 1367 (m), 1328
(w), 1208 (w), 1135 (m), 1083 (s), 1072 (s), 985 (s), 927 (m), 875
(w), 796 (w), 733 (m), 695 (s), 656 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 938.4 (MþNH4þ, 100). HRMS





General procedure A was applied (use of iodobutane). Purification
via column chromatography (gradient elution: hexane/EtOAc 9/1
to 8/2) afforded the title compound 20-d as a colourless glass
(205mg, 0.219mmol, 96%).
Rf 0.17 in hexane/EtOAc 8/2. 1H NMR (400MHz, benzene-d6): d
7.63–7.56 (m, 2H), 7.40–7.28 (m, 10H), 7.24–7.00 (m, 18H), 5.41 (d,
J¼ 3.8 Hz, 1H), 5.38 (s, 1H), 5.34 (d, J¼ 3.5 Hz, 1H), 4.95 (d,
J¼ 11.6Hz, 1H), 4.93 (d, J¼ 11.7 Hz, 1H), 4.81 (d, J¼ 11.4 Hz, 1H),
4.76 (d, J¼ 12.0 Hz, 1H), 4.69 (d, J¼ 11.6 Hz, 1H), 4.68 (d,
J¼ 12.1Hz, 1H), 4.59–4.44 (m, 6H), 4.38 (app t, J¼ 9.3 Hz, 1H), 4.28
(app t, J¼ 9.3 Hz, 1H), 4.19 (dd, J¼ 10.2/4.9 Hz, 1H), 3.92 (app t,
J¼ 6.2 Hz, 1H), 3.89 (app t, J¼ 6.2 Hz, 1H), 3.75–3.48 (m, 8H),
1.58–1.20 (m, 2H), 0.84 (t, J¼ 7.3 Hz, 3H) ppm. 13C NMR (100MHz,
CDCl3): d 139.9 (C), 139.8 (C), 139.1 (C), 139.0 (C), 138.7 (C), 138.5
(C), 128.9 (CH), 128.7 (CH), 128.6 (CH), 128.6 (CH), 128.4 (CH), 128.3
(CH), 128.0 (CH), 127.9 (CH), 127.7 (CH), 127.4 (CH), 127.4 (CH),
126.8 (CH), 101.6 (CH), 94.4 (CH), 93.7 (CH), 83.0 (CH), 82.4 (CH),
80.3 (CH), 79.3 (CH), 78.6 (CH), 75.2 (CH2), 73.8 (CH2), 73.7 (CH2),
72.8 (CH2), 71.9 (CH), 69.5 (CH2), 69.3 (CH2), 63.4 (CH), 33.0 (CH2),
19.7 (CH2), 14.2 (CH) ppm. IR (HATR): 3064 (w), 3030 (w), 2930 (w),
2862 (w), 1496 (w), 1453 (m), 1366 (m), 1329 (w), 1208 (w), 1135
(m), 1086 (s), 1049 (m), 985 (s), 913 (m), 796 (w), 733 (m), 695 (s),
657 (m) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 954.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C58H68NO11
þ [MþNH4]þ 954.4787; found 954.4788.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-(2-methylallyl)-
a,a-D-trehalose (20-e)
General procedure A was applied (use of 3-bromo-2-methylpro-
pene, “methallyl bromide”). Purification via column chromatog-
raphy (gradient elution: hexane/EtOAc 9/1 to 8/2 containing 1%
Et3N) afforded the title compound 20-e as a colourless glass
(203mg, 0.217mmol, 88%).
Rf 0.07 in hexane/EtOAc 9/1. 1H NMR (400MHz, benzene-d6): d
7.64–7.56 (m, 2H), 7.43–7.27 (m, 10H), 7.24–7.02 (m, 18H), 5.41 (d,
J¼ 3.8 Hz, 1H), 5.38 (s, 1H), 5.33 (d, J¼ 3.7 Hz, 1H), 5.10–5.03 (m,
1H), 4.94 (d, J¼ 11.7Hz, 1H), 4.93 (d, J¼ 11.2 Hz, 1H), 4.86–4.81 (m,
1H), 4.78 (d, J¼ 11.4Hz, 1H), 4.77 (d, J¼ 12.0Hz, 1H), 4.70 (d,
J¼ 11.7 Hz, 1H), 4.66 (d, J¼ 12.0 Hz, 1H), 4.59–4.26 (m, 9H), 4.19
(dd, J¼ 10.1/4.9 Hz, 1H), 4.03 (d, J¼ 12.1 Hz, 1H), 3.78–3.48 (m, 7H),
1.61 (s, 3H) ppm. 13C NMR (100MHz, benzene-d6): d 143.0 (C),
139.8 (C), 139.7 (C), 139.0 (C), 139.0 (C), 138.6 (C), 138.5 (C), 128.9
(CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 128.0 (CH),
127.9 (CH), 127.8 (CH), 127.7 (CH), 127.4 (CH), 127.4 (CH), 126.8
(CH), 111.4 (CH2), 101.6 (CH), 94.4 (CH), 93.7 (CH), 83.0 (CH), 82.4
(CH), 80.3 (CH), 79.4 (CH), 79.3 (CH), 78.5 (CH), 76.8 (CH2), 75.4
(CH2), 75.2 (CH2), 73.9 (CH2), 73.6 (CH2), 71.7 (CH), 69.5 (CH2), 69.3
(CH2), 63.4 (CH), 19.7 (CH3) ppm. IR (HATR): 3085 (w), 3065 (w),
3030 (w), 2930 (w), 2862 (w), 1496 (w), 1453 (m), 1366 (m), 1328
(w), 1208 (w), 1155 (m), 1137 (m), 1085 (s), 1075 (s), 1049 (m), 984
(s), 907 (m), 796 (w), 733 (m), 695 (s), 656 (w), 631 (w) cm1. ESMS
[m/z (fragment, intensity), API-ES positive mode]: 952.4 (MþNH4þ,





General procedure A was applied (use of 1-bromo-3-methyl-2-
butene, “prenyl bromide”). Purification via column chromatog-
raphy (gradient elution: hexane/EtOAc 9/1 to 85/15 containing 1%
Et3N) afforded the title compound 20-f as a colourless glass
(665mg, 0.701mmol, 78%).
Rf 0.38 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.63–7.54 (m, 2H), 7.42–7.26 (m, 10H), 7.23–7.01 (m, 18H),
5.53–5.46 (m, 1H), 5.40 (d, J¼ 3.8 Hz, 1H), 5.37 (s), 1H), 5.34 (d,
J¼ 3.7 Hz, 1H), 5.00–4.83 (m, 3H), 4.80–4.66 (m, 3H), 4.59–4.44 (m,
7H), 4.42–4.25 (m, 3H), 4.18 (dd, J¼ 10.2/4.9 Hz, 1H), 3.80–3.69 (m,
3H), 3.62 (dd, J¼ 7.3/3.7 Hz, 1H), 3.60 (dd, J¼ 7.6/3.7 Hz, 1H), 3.54
(app t, J¼ 9.5 Hz, 1H), 3.52 (app t, J¼ 10.4 Hz, 1H), 1.59 (s, 3H),
1.45 (s, 3H) ppm. 13C NMR (100MHz, benzene-d6): d 140.3 (C),
140.2 (C), 139.5 (C), 139.4 (C), 139.1 (C), 138.9 (C), 135.5 (C), 129.3
(CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.7 (CH), 128.4 (CH),
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128.3 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 127.8 (CH), 127.8
(CH), 127.1 (CH), 123.3 (CH), 102.0 (CH), 94.8 (CH), 94.1 (CH), 83.3
(CH), 82.9 (CH), 80.7 (CH), 79.7 (CH), 79.6 (CH), 78.3 (CH), 75.8
(CH2), 75.6 (CH2), 74.1 (CH2), 72.3 (CH), 70.0 (CH2), 69.7 (CH2), 63.8
(CH), 26.1 (CH3), 18.3 (CH3) ppm. IR (HATR): 3085 (w), 3059 (w),
3030 (w), 2930 (w), 2861 (w), 1496 (w), 1453 (m), 1366 (m), 1328
(w), 1279 (vw), 1208 (w), 1153 (m), 1137 (m), 1070 (s), 984 (s), 913
(m), 874 (vw), 840 (w), 796 (w), 732 (s), 695 (s), 656 (m), 631 (w)
cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
966.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C59H68NO11þ
[MþNH4]þ 966.4787; found 966.4791.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-n-decyl-a,a-D-tre-
halose (20-g)
General procedure A was applied (use of bromodecane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 10/0 to 8/2 containing 1% Et3N) afforded the title com-
pound 20-g as a colourless glass (236mg, 0.231mmol, 93%).
Rf 0.07 in hexane/EtOAc 7/3. 1H NMR (400MHz, benzene-d6): d
7.63–7.55 (m, 2H), 7.43–7.27 (m, 10H), 7.26–7.02 (m, 18H), 5.41 (d,
J¼ 3.8 Hz, 1H), 5.37 (s, 1H), 5.34 (d, J¼ 3.7 Hz, 1H), 4.97 (d,
J¼ 11.5Hz, 1H), 4.93 (d, J¼ 11.6 Hz, 1H), 4.85 (d, J¼ 11.5 Hz, 1H),
4.76 (d, J¼ 12.0 Hz, 1H), 4.68 (app d, J¼ 11.5 Hz, 2H), 4.60–4.44 (m,
6H), 4.38 (app t, J¼ 9.3 Hz, 1H), 4.30 (app t, J¼ 9.3 Hz, 1H), 4.18
(dd, J¼ 10.1/4.9 Hz, 1H), 4.00–3.90 (m, 1H), 3.80–3.48 (m, 8H),
1.64–1.47 (m, 2H), 1.43–1.18 (m, 14H), 0.92 (t, J¼ 6.8 Hz, 3H) ppm.
13C NMR (100MHz, benzene-d6): d 139.9 (C), 139.8 (C), 139.1 (C),
139.0 (C), 138.7 (C), 138.5 (C), 128.9 (CH), 128.7 (CH), 128.6 (CH),
128.6 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.9 (CH), 127.7
(CH), 127.6 (CH), 127.4 (CH), 127.4 (CH), 101.6 (CH), 94.4 (CH), 93.7
(CH), 83.0 (CH), 82.4 (CH), 80.3 (CH), 79.3 (CH), 79.3 (CH), 78.6 (CH),
75.4 (CH2), 75.2 (CH2), 73.7 (CH2), 73.7 (CH2), 73.7 (CH2), 73.2 (CH2),
71.9 (CH), 69.6 (CH2), 69.3 (CH2), 63.4 (CH), 32.3 (CH2), 31.0 (CH2),
30.1 (CH2), 30.1 (CH2), 30.0 (CH2), 29.8 (CH2), 26.7 (CH2), 23.1 (CH2),
14.3 (CH3) ppm. IR (HATR): 3085 (w), 3059 (w), 3030 (w), 2924 (m),
2854 (m), 1496 (w), 1453 (m), 1366 (m), 1328 (w), 1208 (w), 1153
(m), 1137 (m), 1087 (s), 1049 (m), 986 (s), 913 (w), 874 (w), 796
(w), 732 (m), 695 (s), 656 (w), 634 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 1038.5 (MþNH4þ, 100). HRMS





In a sealed tube AD-mix a (1.21 g), MeSO2NH2 (106mg, 1.11mmol,
2.5 eq) and (DHQ)2PHAL (95mg, 0.122mmol, 0.28 eq) were dis-
solved in H2O/tert-butanol (1/1, 18.4ml) and the solution was
stirred for 30min. The obtained yellow solution was cooled to
0 C and stirred for 10min at 0 C. To this, a cooled (0 C) solution
of 20-f (418mg, 0.440mmol, 1 eq) in acetone (8.3ml) was added
and the resulting mixture was stirred for 10 d at 0–5 C. An aque-
ous Na2SO3 solution (10% w/v, 3ml) was added and the resulting
mixture was stirred for 2 h at 0 C after which it was transferred to
a separation funnel using H2O (10ml) and EtOAc (30ml). After
separation of the organic layer, the aqueous phase was extracted
with EtOAc (2 30ml). The combined organic layers were washed
with brine (100ml) and concentrated under reduced pressure. The
residue was purified using column chromatography (gradient elu-
tion: hexane/EtOAc 75/25 to 6/4 containing 1% Et3N) to give the
title compound 20-h as a colourless glass (240mg, 0.244mmol,
55%, 73% de based on 1H NMR analysis).
Rf 0.50 in hexane/EtOAc 1/1. 1H NMR (300MHz, CDCl3): d
7.54–7.22 (m, 30H), 5.55 (s, 1H), 5.18–5.11 (m, 2H), 5.05–4.60 (m,
8H), 4.52 (app d, J¼ 12.1 Hz, 1H, A-part of AB-system), 4.41 (app d,
J¼ 12.1 Hz, 1H, B-part of AB-system), 4.31–3.98 (m, 4H), 3.92 (app
t, J¼ 9.3 Hz, 1H), 3.83 (app dd, J¼ 9.5/2.2 Hz, 1H), 3.72–3.28 (m,
9H), 2.94 (br s, OH), 2.29 (br s, OH), 1.10 (app br s, 3H), 1.02 (s,
0.4H, minor diastereoisomer), 0.98 (s, 2.6H, major diastereoiso-
mer) ppm. 13C NMR (75MHz, CDCl3, only major diastereoisomer
visible): d 138.8 (C), 138.4 (C), 138.2 (C), 137.8 (C), 137.6 (C), 137.5
(C), 128.9 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.0
(CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 127.7 (CH),
127.6 (CH), 127.5 (CH), 126.1 (CH), 101.2 (CH), 95.0 (CH), 94.2 (CH),
82.4 (CH), 81.2 (CH), 79.5 (CH), 78.9 (CH), 78.7 (CH), 78.0 (CH), 76.2
(CH), 75.6 (CH2), 75.2 (CH2), 73.7 (CH2), 73.6 (CH2), 73.6 (CH2), 73.0
(CH2), 71.2 (C), 70.5 (CH), 69.0 (CH2), 68.4 (CH2), 63.0 (CH), 26.5
(CH3), 24.5 (CH3) ppm. IR (HATR): 3480 (w, br), 3086 (w), 3064 (w),
3027 (w), 2927 (w), 2863 (w), 1496 (w), 1453 (m), 1368 (m), 1331
(w), 1209 (w), 1135 (m), 1086 (s), 1072 (s), 1047 (m), 1011 (m), 985
(s), 915 (m), 877 (w), 797 (w), 734 (m), 695 (s), 656 (w) cm1. ESMS
[m/z (fragment, intensity), API-ES positive mode]: 1000.3
(MþNH4þ, 100). ESMS [m/z (fragment, intensity), API-ES negative
mode]: 1041.3 (MþOAc-, 100). HRMS (ESI-TOF): calcd. for
C59H70NO13 [MþNH4]þ 1000.4842; found 1000.4865.
4-O-Methyl-a,a-D-trehalose (21-a)
General procedure C was applied. As the product was poorly sol-
uble in MeOH, the celite layer was additionally washed with water
and the filtrate was lyophilised. The resulting solid was washed
with MeOH to afford the title compound 21-a as a white solid
(46.7mg, 0.131mmol, 80%).
Rf 0.30 in CH3CN/H2O 8/2, 0.35 in CH2Cl2/MeOH 6/4.
1H NMR
(400MHz, D2O): d 5.14 (d, J¼ 3.8 Hz, 1H), 5.14 (d, J¼ 3.8 Hz, 1H),
3.89 (app t, J¼ 9.6 Hz, 1H), 3.85–3.68 (m, 7H), 3.62 (dd, J¼ 9.8/
3.9 Hz, 1H), 3.60 (dd, J¼ 9.8/3.9 Hz, 1H), 3.54 (s, 3H), 3.40 (app t,
J¼ 9.4 Hz, 1H), 3.22 (app t, J¼ 9.4 Hz, 1H) ppm. 13C NMR
(100MHz, D2O): d 93.2 (CH), 93.1 (CH), 79.4 (CH), 72.5 (CH), 72.3
(CH), 72.1 (CH), 71.1 (CH), 71.0 (CH), 71.0 (CH), 69.7 (CH), 60.5
(CH2), 60.2 (CH2), 60.1 (CH3) ppm. IR (HATR): 3488 (w), 3478 (w),
3400 (br, m), 3300 (w), 3160 (w), 3012 (w), 2976 (w), 2938 (w),
2920 (w), 2874 (w), 1654 (w), 1594 (w), 1456 (m), 1414 (w), 1380
(w), 1354 (w), 1304 (w), 1288 (w), 1250 (w), 1206 (w), 1190 (w),
1148 (m), 1132 (m), 1116 (m), 1098 (m), 1072 (m), 1044 (m), 1022
(m), 980 (s), 964 (s), 938 (m), 904 (m), 868 (w), 854 (w), 828 (w),
804 (w), 770 (w), 726 (w), 710 (w), 698 (w), 654 (w) cm1. ESMS
[m/z (fragment, intensity), API-ES positive mode]: 374.1 (MþNH4þ,
100), 339.1 (M-H2OþHþ, 40), 177.1 (M-glucoseþHþ, 85). HRMS




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 21-b as a white solid (59.9mg, 0.162mmol, 90%).
Rf 0.27 in CH3CN/H2O 8/2, 0.22 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.10 (d, J¼ 3.8 Hz, 1H), 5.08 (d, J¼ 3.7 Hz, 1H),
3.95–3.72 (m, 7H), 3.71–3.60 (m, 3H), 3.51–3.42 (m, 2H), 3.33–3.27
(m, 1H), 3.21 (dd, J¼ 9.7/9.2 Hz, 1H), 1.17 (t, J¼ 7.0 Hz, 3H) ppm.
13C NMR (100MHz, CD3OD): d 95.1 (CH), 95.0 (CH), 79.6 (CH), 74.6
(CH), 74.5 (CH), 73.8 (CH), 73.3 (CH), 73.2 (CH), 72.9 (CH), 71.9 (CH),
69.1 (CH2), 62.6 (CH2), 62.1 (CH2), 16.0 (CH3) ppm. IR (HATR): 3308
(br, m), 2970 (w), 2929 (w), 1440 (w), 1413 (w), 1374 (w), 1332 (w),
1248 (w), 1204 (w), 1145 (m), 1103 (m), 1030 (m), 984 (s), 941 (m),
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877 (w), 843 (w), 799 (w), 706 (w) cm1. [a]D
25 þ164 (c 0.310,
MeOH). ESMS [m/z (fragment, intensity), API-ES positive mode]:
388.1 (MþNaþ, 100). HRMS (ESI-TOF): calcd. for C14H26NaO11þ
[MþNa]þ 393.1367; found 393.1365.
4-O-n-Propyl-a,a-D-trehalose (21-c)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 21-c as a white solid (57.3mg, 0.149mmol, 90%).
Rf 0.30 in CH3CN/H2O 8/2, 0.30 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.10 (d, J¼ 3.9 Hz, 1H), 5.09 (d, J¼ 3.9 Hz, 1H),
3.92–3.72 (m, 7H), 3.71–3.62 (m, 2H), 3.58–3.43 (m, 3H), 3.36–3.28
(m, 1H), 3.20 (dd, J¼ 9.8/9.2 Hz, 1H), 1.67–1.48 (m, 2H), 0.92 (t,
J¼ 7.4 Hz, 3H) ppm. 13C NMR (100MHz, CD3OD): d 95.0 (CH), 79.6
(CH), 75.5 (CH2), 74.6 (CH), 74.5 (CH), 73.7 (CH), 73.4 (CH), 73.2
(CH), 72.9 (CH), 71.8 (CH), 62.6 (CH2), 62.1 (CH2), 24.5 (CH2), 10.9
(CH3) ppm. IR (HATR): 3326 (br, m), 2934 (w), 2880 (w), 1455 (w),
1416 (w), 1363 (w), 1257 (w), 1204 (w), 1145 (m), 1103 (m), 1072
(m), 1030 (m), 987 (s), 843 (w), 802 (w), 706 (w), 617 (w) cm1.
[a]D
25 þ183 (c 0.557, MeOH). ESMS [m/z (fragment, intensity),
API-ES positive mode]: 402.2 (MþNH4þ, 100). HRMS (ESI-TOF):
calcd. for C15H28NaO11
þ [MþNa]þ 407.1524; found 407.1520.
4-O-n-Butyl-a,a-D-trehalose (21-d)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 6/4) afforded the
title compound 21-d as a white solid (75mg, 0.188mmol, 100%).
Rf 0.40 in CH3CN/H2O 8/2, 0.14 in CH2Cl2/MeOH 8/2.
1H NMR
(300MHz, CD3OD): d 5.09 (d, J¼ 4.1 Hz, 1H), 5.08 (d, J¼ 4.0 Hz, 1H),
3.94–3.50 (m, 10H), 3.50–3.40 (m, 2H), 3.35–3.25 (m, 1H), 3.19 (app
t, J¼ 9.9 Hz, 1H), 1.64–1.26 (m, 4H), 0.92 (t, J¼ 7.3 Hz, 3H) ppm.
13C NMR (75MHz, CD3OD): d 95.1 (CH), 95.0 (CH), 79.7 (CH), 74.7
(CH), 74.5 (CH), 73.8 (CH), 73.6 (CH2), 73.4 (CH), 73.3 (CH), 72.9
(CH), 71.9 (CH), 62.6 (CH2), 62.2 (CH2), 33.6 (CH2), 20.3 (CH2), 14.3
(CH3) ppm. IR (HATR): 3338 (m, br), 2934 (w), 2872 (w), 1455 (w,
br), 1361 (w, br), 1258 (w), 1236 (w), 1209 (w), 1145 (m), 1104 (m),
1074 (m), 1040 (m), 990 (s), 939 (w), 909 (w), 842 (w), 801 (w)
cm1. [a]D
22 þ182 (c 0.10, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES positive mode]: 416.2 (MþNH4þ, 100). HRMS (ESI-
TOF): calcd. for C16H30NaO11 [MþNa]þ 421.1680; found 421.1677.
4-O-Isobutyl-a,a-D-trehalose (21-e)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 85/15 to 7/3) afforded
the title compound 21-e as a white solid (77mg,
0.193mmol, 100%).
Rf 0.16 in CH2Cl2/MeOH 8/2.
1H NMR (400MHz, CD3OD): d
5.12–5.07 (m, 2H), 3.93–3.73 (m, 6H), 3.73–3.63 (m, 3H), 3.51–3.43
(m, 2H), 3.35–3.28 (m, 2H), 3.19 (dd, J¼ 9.9/9.0 Hz, 1H), 1.83 (app
nonaplet, J¼ 6.6 Hz, 1H), 0.91 (d, J¼ 7.0 Hz, 3H), 0.89 (d, J¼ 7.0 Hz,
3H) ppm. 13C NMR (100MHz, CD3OD): d 95.0 (CH), 94.9 (CH), 80.7
(CH2), 79.6 (CH), 74.7 (CH), 74.5 (CH), 73.7 (CH), 73.4 (CH), 73.2
(CH), 72.9 (CH), 71.8 (CH), 62.6 (CH2), 62.2 (CH2), 30.2 (CH), 19.9
(CH3), 19.7 (CH3) ppm. IR (HATR): 3326 (br, m), 2951 (w), 2925 (m),
2873 (w), 1458 (w), 1414 (w), 1380 (w), 1365 (w), 1336 (w), 1259
(w), 1204 (w), 1145 (m), 1104 (m), 1031 (m), 983 (s), 951 (m), 841
(w), 802 (w), 732 (w), 706 (w), 613 (w) cm1. [a]D
25 þ151 (c 0.77,
MeOH). ESMS [m/z (fragment, intensity), API-ES positive mode]:
416.2 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C16H30NaO11þ
[MþNa]þ 421.1680; found 421.1676.
4-O-Isopentyl-a,a-D-trehalose (21-f)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 7/3) afforded the
title compound 21-f as a white solid (27.2mg, 0.066mmol, 39%).
Rf 0.46 in CH3CN/H2O 8/2, 0.36 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.10 (d, J¼ 3.8 Hz, 1H), 5.08 (d, J¼ 3.8 Hz, 1H),
3.95–3.71 (m, 7H), 3.71–3.57 (m, 3H), 3.51–3.42 (m, 2H), 3.36–3.27
(m, 1H), 3.19 (dd, J¼ 9.8/9.1 Hz, 1H), 1.70 (app nonaplet, J¼ 6.7 Hz,
1H), 1.56–1.35 (m, 2H), 0.91 (d, J¼ 6.7 Hz, 3H), 0.90 (d, J¼ 6.7 Hz,
3H) ppm. 13C NMR (100MHz, CD3OD): d 95.1 (CH), 95.0 (CH), 79.6
(CH), 74.7 (CH), 74.5 (CH), 73.8 (CH), 73.4 (CH), 73.2 (CH), 72.9 (CH),
72.2 (CH2), 71.9 (CH), 62.6 (CH2), 62.2 (CH2), 40.4 (CH2), 26.0 (CH),
23.2 (CH3), 22.9 (CH3) ppm. IR (HATR): 3327 (br, m), 2953 (w), 2927
(w), 2875 (w), 1461 (w), 1419 (w), 1385 (w), 1366 (w), 1335 (w),
1240 (w), 1204 (w), 1145 (w), 1103 (m), 1069 (m), 1030 (m), 986
(s), 843 (w), 800 (w), 706 (w), 614 (w) cm1. [a]D
25 þ177 (c 0.09,
MeOH). ESMS [m/z (fragment, intensity), API-ES positive mode]:
430.2 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C17H32NaO11þ
[MþNa]þ 435.1837; found 435.1841.
4-O-n-Decyl-a,a-D-trehalose (21-g)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 21-g as a colourless glass (98mg,
0.203mmol, 98%).
Rf 0.23 in CH2Cl2/MeOH 8/2.
1H NMR (400MHz, CD3OD): d 5.10
(d, J¼ 3.8 Hz, 1H), 5.09 (d, J¼ 3.8 Hz, 1H), 3.92–3.72 (m, 7H),
3.71–3.52 (m, 3H), 3.51–3.43 (m, 2H), 3.33–3.28 (m, 1H), 3.19 (dd,
J¼ 9.8/9.0 Hz, 1H), 1.65–1.47 (m, 2H), 1.43–1.20 (m, 14H), 0.89 (t,
J¼ 6.9 Hz, 3H) ppm. 13C NMR (100MHz, CD3OD): d 95.0 (CH), 94.9
(CH), 79.6 (CH), 74.6 (CH), 74.5 (CH), 73.9 (CH2), 73.8 (CH), 73.4
(CH), 73.2 (CH), 72.9 (CH), 71.9 (CH), 62.6 (CH2), 62.2 (CH2), 33.0
(CH2), 31.4 (CH2), 30.8 (CH2), 30.7 (CH2), 30.7 (CH2), 30.4 (CH2), 27.2
(CH2), 23.7 (CH2), 14.4 (CH3) ppm. IR (HATR): 3320 (m, br), 2922
(m), 2854 (w), 1650 (w), 1455 (w), 1370 (w), 1337 (w), 1145 (m),
1101 (m), 1076 (m), 1030 (s), 988 (s), 940 (w), 912 (w), 840 (w), 803
(w), 720 (w), 620 (w) cm1. [a]D
25 þ142 (c 0.750, MeOH). ESMS
[m/z (fragment, intensity), API-ES positive mode]: 500.3 (MþNH4þ,




General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 8/2 to 6/4) afforded the
title compound 2 as a white solid (68mg, 0.153mmol, 100%).
Literature data is available 24,30.
Rf 0.17 in CH3CN/H2O 8/2, 0.32 in CH2Cl2/MeOH 6/4.
1H NMR
(300MHz, CDCl3, two diastereoisomers): d 5.10 (app d, J¼ 4.0 Hz,
1H), 5.08 (app d, J¼ 3.8 Hz, 1H), 4.05–3.60 (m, 10H), 3.57–3.41 (m,
3H), 3.35–3.22 (m, 2H), 1.21–1.13 (m, 6H) ppm. 13C NMR (75MHz,
CDCl3, only major diastereoisomer visible): d 95.1 (CH), 95.0 (CH),
80.4 (CH), 78.2 (CH), 74.7 (CH2), 74.5 (CH), 74.4 (CH), 73.8 (CH), 73.4
(CH), 73.2 (CH), 72.8 (CH), 72.8 (C), 71.9 (CH), 62.6 (CH2), 62.2 (CH2),
26.5 (CH3), 25.4 (CH3) ppm. IR (HATR): 3309 (m, br), 2923 (w), 1362
(w, br), 1229 (w), 1145 (m), 1074 (m), 1033 (m), 985 (s), 934 (m),
855 (w), 843 (w), 800 (w) cm1. [a]D
22 þ228 (c 0.10, MeOH). ESMS
[m/z (fragment, intensity), API-ES positive mode]: 462.2 (MþNH4þ,
100). HRMS (ESI-TOF): calcd. for C17H32NaO13 [MþNa]þ 467.1735;
found 467.1734.
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2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-(N-n-propylcar-
bamoyl)-a,a-D-trehalose (22-a)
General procedure B was applied (use of n-propyl isocyanate).
Purification via column chromatography (gradient elution: tolu-
ene/acetone 99/1 to 95/5) afforded the title compound 22-a as a
colourless oil (372mg, 0.352mmol, 68%).
Rf 0.34 in hexane/EtOAc 7/3, 0.19 in toluene/acetone 95/5. 1H
NMR (400MHz, CDCl3): d 7.36–7.09 (m, 35H), 5.26 (d, J¼ 3.5 Hz,
1H),5.21 (d, J¼ 3.5 Hz, 1H), 4.98 (d, J¼ 11.0 Hz, 1H), 4.90–4.35 (m,
15H), 3.41 (d, J¼ 1.7 Hz, 1H), 3.45–3.37 (m, 2H),0.35 (dd, J¼ 10.6/
5.5 Hz, 1H), 3.08 (q, J¼ 6.5 Hz, 2H), 1.49–1.37 (m, 2H), 0.86 (t,
J¼ 7.3 Hz, 3H) ppm. 13C NMR (100MHz, CDCl3): d 155.3 (C), 138.9
(C), 138.7 (C), 138.4 (C), 138.2 (C), 138.1, 138.0 (C), 137.8 (C), 128.3
(CH), 128.2 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH),
127.7 (CH), 127.7 (CH), 127.6 (CH), 127.5 (CH), 127.5 (CH), 127.4
(CH), 127.4 (CH), 93.6 (CH), 93.5 (CH), 81.8 (CH), 79.2 (CH), 78.9
(CH), 77.7 (CH), 75.5 (CH2), 75.0 (CH2), 74.9 (CH2), 73.6 (CH2), 73.5
(CH2), 73.0 (CH2), 72.4 (CH2), 71.3 (CH), 70.6 (CH), 69.8 (CH), 69.1
(CH2), 68.1 (CH2), 42.8 (CH2), 23.1 (CH2), 11.2 (CH3) ppm. IR (HATR):
3419 (w), 3331 (w), 3060 (w), 3030 (w), 2926 (w), 2870 (w), 1723
(m), 1514 (w), 1496 (m), 1453 (m), 1361 (m), 1332 (w), 1312 (w),
1263 (m), 1231 (m), 1212 (m), 1140 (m), 1097 (s), 1067 (s), 1025
(m), 993 (s), 917 (w), 848 (w), 801 (w), 733 (s), 695 (s) cm1. ESMS
[m/z (fragment, intensity), API-ES positive mode]: 1075.4
(MþNH4þ, 42), 518.2 (4-O-n-propylcarbamoyl-2-O,3-O,6-O-triben-
zylglucosyl cation, 100). HRMS (ESI-TOF): calcd. for C65H71NNaO12
þ
[MþNa]þ 1080.4869; found 1080.4847.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-(N-isopropylcar-
bamoyl)-a,a-D-trehalose (22-b)
General procedure B was applied (use of isopropyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 75/25) afforded the title compound 22-b as a colour-
less glass (447mg, 0.422mmol, 82%).
Rf 0.31 in hexane/EtOAc 7/3. 1H NMR (400MHz, CDCl3): d
7.38–7.19 (m, 33H), 7.16–7.11 (m, 2H), 5.29 (d, J¼ 3.3 Hz, 1H), 5.23
(d, J¼ 3.5 Hz, 1H), 5.00 (d, J¼ 11.0 Hz, 1 H), 4.87 (dd, J¼ 11.0/
2.4 Hz, 2H), 4.83 (d, J¼ 10.9 Hz, 1H),) , 4.73 (s, 3H), 4.72–4.61 (m,
4H), 4.56 (d, J¼ 12.1Hz, 1H), 4.53–4.36 (m, 2H), 4.50 (d, J¼ 2.1 Hz,
1H), 4.47 (s, 1H), 4.22–4.14 (m, 2H), 4.05 (t, J¼ 9.5 Hz, 1H), 3.96 (t,
J¼ 9.5 Hz, 1H), 3.8 (q, J¼ 6.0 Hz, 1H), 3.69 (t, J¼ 9.5 Hz, 1H), 3.63
(dt, J¼ 9.7/3.3 Hz, 2H), 3.55 (dd, J¼ 10.8/3.2 Hz, 1H), 3.50–3.40 (m,
2H), 3.36 (dd, J¼ 10.7/5.6 Hz, 1H) 11.12 (s, 3H)) 1.09 (s, 3H) ppm.
13C NMR (100MHz, CDCl3): d 154.4 (C), 138.9 (C), 138.7 (C), 138.4
(C), 138.2 (C), 139.1 (C), 138.0 (C), 137.8 (C), 128.3 (CH), 128.3 (CH),
128.2 (CH), 128.2 (CH), 128.2 (CH), 128.0 (CH),127.9 (CH), 127.8
(CH), 127.8 (CH), 127.7 (CH), 127.6 (CH), 127.6 (CH), 127.5 (CH),
127.5 (CH), 127.4 (CH), 127.4 (CH), 127.4 (CH), 93.6 (CH), 93.5 (CH),
81.8 (CH), 79.2 (CH), 79.1 (CH), 79.0 (CH), 77.7 (CH), 75.5 (CH2), 75.0
(CH2), 74.9 (CH2), 73.7 (CH2), 73.5 (CH2), 73.0 (CH2), 72.4 (CH2), 71.1
(CH), 70.6 (CH), 69.8 (CH), 69.1 (CH2), 68.1 (CH2), 43.1 (CH), 23.0
(CH3), 22.9 (CH3) ppm. IR (HATR): 3410 (w), 3327 (w), 3059 (w),
3030 (w), 2972 (w), 2923 (w), 2868 (w), 1723 (m), 1496 (m), 1453
(m), 1387 (w), 1362 (m), 1322 (w), 1269 (w), 1230 (m), 1156 (m),
1135 (m), 1097 (m), 1068 (s), 1026 (m), 995 (s), 952 (m), 852 (w),
797 (w), 733 (s), 695 (s), 641 (m) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 1075.4 (MþNH4þ, 42), 518.2 (4-
O-isopropylcarbamoyl-2-O,3-O,6-O-tribenzylglucosyl cation, 100).





General procedure B was applied (use of cyclohexyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 75/25) afforded the title compound 22-c as a colour-
less oil (499mg, 88%).
Rf 0.31 in hexane/EtOAc 7/3. 1H NMR (400MHz, CDCl3): d
7.37–7.17 (m, 33H), 7.16–7.10 (m, 2H), 5.29 (d, J¼ 3.5 Hz, 1H), 5.23
(d, J¼ 3.5 Hz, 1H), 4.99 (d, J¼ 10.9 Hz, 1H), 4.91–4.83 (m, 2H), 4.81
(d, J¼ 10.7 Hz, 1H), 4.77–4.67 (m, 3H), 4.65 (m, 2H), 4.62 (m, 1H),
4.57 (s, 1H), 4.54 (s, 1H), 4.53–3.35 (m, 4H), 4.21–4.14 (m, 2H), 4.04
(t, J¼ 9.3 Hz, 1H), 3.96 (t, J¼ 9.5 Hz, 1H), 3.68 (t, J¼ 9.6 Hz, 1H),
3.62 (dt, J¼ 9.7/3.7 Hz, 2H), 3.55 (dd, J¼ 10.7/3.2 Hz, 1H), 3.42 (dt,
J¼ 10.6/2.3 Hz, 3H), 3.36 (dd, J¼ 10.7/5.6 Hz, 1H), 1.95–1.80 (m,
2H), 1.75–1.60 (m, 3H), 1.42–1.26 (m, 2H), 1.22– 1.00 (m, 3H) ppm.
13C NMR (100MHz, CDCl3): d 154.4 (C), 138.9 (C), 138.7 (C), 138.4
(C), 138.2 (C), 138.1 (C), 138.0 (C), 137.8 (C), 128.3 (CH), 128.3 (CH),
128.2 (CH), 128.2 (CH), 128.2 (CH), 128.0 (CH), 127.9 (CH), 127.9
(CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 127.6 (CH), 127.5 (CH),
127.5 (CH), 127.4 (CH), 127.4 (CH), 93.6 (CH), 93.5 (CH), 81.1 (CH),
79.2 (CH), 79.1 (CH), 78.9 (CH), 77.7 (CH), 75.5 (CH2), 75.0 (CH2),
74.9 (CH2), 73.7 (CH2), 73.5 (CH2), 73.0 (CH2), 72.4 (CH2), 71.2 (CH),
70.6 (CH), 69.8 (CH), 69.1 (CH2), 68.1 (CH2), 49.8 (CH), 33.4 (CH2),
33.3 (CH2), 25.5 (CH2), 24.7 (CH2) ppm. IR (HATR): 3410 (w), 3060
(w), 3032 (w), 2928 (w), 2854 (w), 1723 (m), 1496 (m), 1453 (m),
1361 (w), 1315 (w), 1271 (w), 1252 (w), 1212 (m), 1155 (m), 1140
(m), 1097 (s), 1059 (s), 1027 (s), 994 (s), 892 (w), 799 (w), 733 (s),
695 (s) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 1098.4 (MþHþ, 10), 558.2 (4-O-cyclohexylcarbamoyl-2-O,3-
O,6-O-tribenzylglucosyl cation, 100). HRMS (ESI-TOF): calcd. for
C68H75NNaO12
þ [MþNa]þ 1120.5181; found 1120.5143.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-(N-phenylcarba-
moyl)-a,a-D-trehalose (22-d)
General procedure B was applied (use of phenyl isocyanate).
Purification via column chromatography (gradient elution: tolu-
ene/acetone 99/1 to 95/5) afforded the partially purified title com-
pound 22-d as a colourless oil which was used as such in the
next step.
Rf 0.38 in hexane/EtOAc 7/3.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-(N-benzylcarba-
moyl)-a,a-D-trehalose (22-e)
General procedure B was applied (use of benzyl isocyanate).
Purification via column chromatography (gradient elution: tolu-
ene/acetone 100/0 to 97/3) afforded the title compound 22-e as a
colourless oil (283mg, 0.256mmol, 50%).
Rf 0.33 in hexane/EtOAc 7/3. 1H NMR (400MHz, CDCl3): d
7.36–7.10 (m, 40H), 5.28 (d, J¼ 3.5 Hz, 1H), 5.23 (d, J¼ 3.4 Hz, 1H),
5.02–4.91 (m, 2H), 4.86 (d, J¼ 10.4 Hz, 2H), 4.81–4.75 (m, 2H),
4.75–4.60 (m, 5H), 4.56 (d, J¼ 12.1 Hz, 1H), 4.48 (q, J¼ 12.8 Hz, 1H)
4.47 (m, 2H), 4.41 (d, J¼ 12.1Hz, 1H), 4.32 (m, 2H), 4.21–4.14 (m,
2H), 4.03 (t, J¼ 9.3 Hz, 1H), 3.96 (t, J¼ 9.3 Hz, 1H), 3.69 (t,
J¼ 9.7 Hz, 1H), 3.63 (dd, J¼ 9.7/3.5, 1H), 3.61 (dd, J¼ 8.3/3.4 Hz,
1H), 3.55 (dd, J¼ 10.7/3.3 Hz, 1H), 3.47–3.40 (m, 2H), 3.36 (dd,
J¼ 10.4/5.0 Hz, 1H) ppm. 13C NMR (100MHz, CDCl3): d 155.3 (C),
138.9 (C), 138.7 (C), 138.4 (C),138.3 (C), 138.2 (C), 138.1 (C), 138.0
(C), 137.8 (C), 128.7 (CH), 128.3 (CH), 128.2 (CH), 128.2 (CH), 128.0
(CH),127.9 (CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 127.6 (CH),
127.6 (CH), 127.5 (CH), 127.5 (CH), 127.5 (CH), 127.4 (CH), 127.4
(CH), 93.6 (CH), 93.5 (CH), 81.8 (CH), 79.2 (CH), 79.0 (CH), 78.9 (CH),
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77.7 (CH), 75.5 (CH2), 75.0 (CH2), 74.9 (CH2), 73.7 (CH2), 73.5 (CH2),
73.0 (CH2), 72.5 (CH2), 71.6 (CH), 70.6 (CH), 68.7 (CH), 69.0 (CH2),
68.1 (CH2), 45.2 (CH2) ppm. IR (HATR): 3410 (w), 3332 (w), 3059
(w), 3031 (w), 2920 (w), 2868 (w), 1724 (m), 1510 (w), 1496 (w),
1453 (w), 1362 (w), 1247 (w), 1208 (w), 1154 (m), 1138 (m), 1097
(m), 1068 (m), 1026 (m), 995 (m), 850 (w), 797 (w), 734 (w), 695 (s),
645 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 1123.4 (MþNH4þ, 95), 566.2 (4-O-benzylcarbamoyl-2-O,3-
O,6-O-tribenzylglucosyl cation, 100). HRMS (ESI-TOF): calcd. for
C69H71NNaO12
þ [MþNa]þ 1128.4868; found 1128.4828.
2,3,6,2’,3’-Penta-O-benzyl-4’,6’-O-benzylidene-4-O-[N-(2-phenethyl)-
carbamoyl]-a,a-D-trehalose (22-f)
General procedure B was applied (use of phenethyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 9/1 to 75/25) afforded the title compound 22-f as a white
foam (130mg, 0.116mmol, 57%).
Rf 0.28 in hexane/EtOAc. 1H NMR (400MHz, CDCl3): d 7.35–7.05
(m, 40H), 5.25 (d, J¼ 3.3 Hz, 1H), 5.20 (d, J¼ 3.4 Hz, 1H), 5.00–4.35
(m, 16H), 4.20–4.10 (d, J¼ 9.9 Hz, 2H), 4.01 (t, J¼ 7.8 Hz, 1H), 3.91
(t, J¼ 9.4 Hz, 1H), 3.67 (t, J¼ 9.5 Hz, 1H), 3.62–3.56 (m, 2H), 3.52
(dd, J¼ 10.7/3.4 Hz, 1H), 3.43–3.36 (m, 3H), 3.35–3.30 (m, 1H),
2.79–2.63 (m, 2H) ppm. 13C NMR (100MHz, CDCl3): d 155.2 (C),
138.9 (C), 138.7 (C), 138.6 (C), 138.4 (C), 138.2 (C), 138.0 (C), 138.0
(C), 137.8 (C), 128.7 (CH), 128.6 (CH), 128.3 (CH), 128.2 (CH), 128.2
(CH), 128.2 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH),
127.7 (CH), 127.6 (CH), 127.6 (CH), 127.5 (CH), 127.5 (CH), 127.4
(CH), 127.4 (CH), 127.4 (CH), 126.5 (CH), 93.6 (CH), 93.5 (CH), 81.7
(CH), 79.1 (CH), 78.9 (CH), 77.6 (CH), 75.5 (CH2), 75.0 (CH2), 74.9
(CH2), 73.6 (CH2), 73.5 (CH2), 73.0 (CH2), 72.4 (CH2), 69.0 (CH2), 68.1
(CH2), 42.1 (CH2), 36.0 (CH2) ppm. IR (HATR): 3414 (w), 3336 (w),
3064 (w), 3028 (w), 2922 (w), 2868 (w), 1726 (m), 1496 (m), 1453
(m), 1394 (w), 1362 (m), 1331 (w), 1241 (m), 1208 (w), 1154 (m),
1140 (m), 1098 (s), 1066 (s), 1026 (s), 995 (s), 920 (w), 852 (w), 802
(w), 733 (s), 695 (s), 646 (w) cm1. ESMS [m/z (fragment, intensity),
API-ES positive mode]: 1137.4 (MþNH4þ, 28), 580.2 (4-O-phene-
thylcarbamoyl-2-O,3-O,6-O-tribenzylglucosyl cation, 100). HRMS





General procedure B was applied (use of n-octyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 95/5 to 75/25) afforded the partially purified title com-
pound 22-g as a colourless oil which was used as such in the
next step.
Rf 0.45 in hexane/EtOAc 7/3.
4-O-(N-n-Propylcarbamoyl)-a,a-D-trehalose (23-a)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 10/0 to 7/3) afforded
the title compound 23-a as a white foam (134mg,
0.314mmol, 89%).
Rf 0.43 in CH3CN/H2O 8/2.
1H NMR (400MHz, CD3OD): d 5.14
(d, J¼ 3.8 Hz, 1H), 5.11 (d, J¼ 3.8 Hz, 1H), 4.53 (t, J¼ 9.6 Hz, 1H),
3.98–3.90 (m, 2H), 3.85–3.74 (m, 3H), 3.67 (dd, J¼ 12.0/5.5 Hz, 1H),
3.62–3.50 (m, 3H), 3.48 (dd, J¼ 9.8/3.8 Hz, 1H), 3.32 (m, 1H), 3.07
(dt, J¼ 7.0/1.5 Hz, 2H), 1.56–1.45 (m, 2H), 0.91 (t, J¼ 7.5 Hz, 3H)
ppm. 13C NMR (100MHz, CD3OD): d 158.8 (C), 95.1 (CH), 94.8 (CH),
74.5 (CH), 73.8 (CH),73.5 (CH), 73.4 (CH),73.1 (CH), 72.4 (CH), 72.1
(CH), 71.9 (CH), 62.6 (CH2), 62.4 (CH2), 43.7 (CH2), 24.0 (CH2), 11.5
(CH3) ppm. IR (HATR): 3336 (m, br), 2938 (w), 1716 (m), 1522 (m),
1442 (w), 1361 (w), 1317 (w), 1267 (m), 1230 (m), 1144 (m), 1104
(m), 1086 (m), 1047 (m), 1025 (s), 991 (s), 961 (m), 922 (w), 897
(w), 837 (w), 810 (w), 766 (w), 720 (w) cm1. [a]D
22 þ162 (c 0.10,
MeOH). ESMS [m/z (fragment, intensity), API-ES positive mode]:
428.1 (MþHþ, 100).
4-O-(N-Isopropylcarbamoyl)-a,a-D-trehalose (23-b)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 6/4) afforded the
title compound 23-b as a white foam (129mg, 0.302mmol, 76%).
Rf 0.59 in CH3CN/H2O 8/2, 0.12 in CH2Cl2/MeOH 8/2.
1H NMR
(400MHz, CD3OD): d 5.14 (d, J¼ 3.8 Hz, 1H), 5.11 (d, J¼ 3.8 Hz, 1H),
4.53 (dd, J¼ 10.4/9.5 Hz, 1H), 3.97–3.89 (m, 2H), 3.85–3.78 (m, 1H),
3.77 (m, 1H), 3.76–3.62 (m, 2H), 3.60–3.53 (m, 2H), 3.48 (dd,
J¼ 9.8/3.8 Hz, 1H), 3.31 (d, J¼ 9.5 Hz, 1H), 11.14 (s, 3H), 1.14 (s, 3H)
ppm. 13C NMR (100MHz, CD3OD): d 157.9 (C), 95.0 (CH), 94.8 (CH),
74.5 (CH), 73.8 (CH), 73.4 (CH), 73.1 (CH), 72.4 (CH), 72.1 (CH), 71.9
(CH), 62.6 (CH2), 62.4 (CH2), 44.2 (CH), 22.8 (CH) ppm. IR (HATR):
3301 (m, br), 2936 (w), 1694 (m), 1540 (w), 1457 (w), 1325 (w),
1256 (m), 1138 (m), 1108 (m), 1074 (m), 1031 (s), 992 (s), 946 (m),
914 (w), 841 (w), 806 (w) cm1. [a]D
22 þ190 (c 0.10, MeOH). ESMS
[m/z (fragment, intensity), API-ES positive mode]: 428.2
(MþHþ, 100).
4-O-(N-Cyclohexylcarbamoyl)-a,a-D-trehalose (23-c)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 6/4) afforded the
title compound 23-c as a white foam (116mg, 0.248mmol, 58%).
Rf 0.54 in CH3CN/H2O 8/2, 0.59 in CH2Cl2/MeOH 6/4.
1H NMR
(300MHz, D2O): d 5.20 (d, J¼ 4.5 Hz, 1H), 5.16 (d, J¼ 3.8 Hz, 1H),
4.56 (t, J¼ 9.6 Hz, 1H), 3.99 (t, J¼ 9.8 Hz, 1H), 3.86–3.55 (m, 9H),
3.42 (t, J¼ 9.2 Hz, 1H), 3.4 (s, 1H), 1.86–1.76 (m, 2H), 1.73–1.64 (m,
2H), 1.60–1.50 (m, 1H), 1.35–1.05 (m, 5H) ppm. 13C NMR (75MHz,
D2O): d 157.6 (C), 94.0 (CH), 93.8 (CH), 73.2 (CH), 72.9 (CH), 72.1
(CH), 71.7 (CH), 71.5 (CH), 71.3 (CH), 71.1 (CH), 70.3 (CH), 61.2
(CH2), 61.0 (CH2), 50.8 (CH), 33.0 (CH2), 25.6 (CH2), 25.0 (CH2) ppm.
IR (HATR): 3244 (m, br), 2943 (m), 2857 (w), 1678 (s), 1465 (w),
1447 (w), 1409 (m), 1374 (w), 1347 (w), 1329 (w), 1265 (w), 1133
(m), 1102 (m), 1076 (m), 1046 (s), 1037 (s), 1018 (s), 993 (s), 953
(m), 929 (w), 890 (w), 868 (w), 805 (w), 789 (w), 720 (w), 703 (w)
cm1. [a]D
22 þ171 (c 0.10, MeOH). ESMS [m/z (fragment, inten-
sity), API-ES positive mode]: 468.2 (MþHþ, 55), 288.1 (M-
glucoseþHþ, 100).
4-O-(N-Phenylcarbamoyl)-a,a-D-trehalose (23-d)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 10/0 to 7/3) afforded
the title compound 23-d as a white foam (55mg, 0.119mmol,
16% over two steps).
Rf 0.46 in CH3CN/H2O 8/2.
1H NMR (400MHz, D2O): d 4.41–7.35
(m, 4H), 7.20–7.14 (m, 1H), 5.22 (d, J¼ 3.9 Hz, 1H), 5.18 (d,
J¼ 3.8 Hz, 1H), 4.72 (d, J¼ 9.9 Hz, 1H), 4.08 (t, J¼ 9.8 Hz, 1H),
4.06–3.97 (m, 1H), 3.87–3.79 (m, 3H), 3.78–3.70 (m, 3H), 3.68– 3.60
(m, 2H), 3.43 (t, J¼ 9.5 Hz, 1H) ppm. 13C NMR (100MHz, D2O): d ):
155.7 (C), 137.9 (C), 130.0 (CH), 125.1 (CH), 120.8 (CH), 94.1 (CH),
93.9 (CH), 73.2 (CH), 72.9 (CH), 72.4 (CH), 71.7 (CH), 71.5 (CH), 71.3
(CH), 70.9 (CH), 70.3 (CH), 61.2 (CH2), 60.9 (CH2) ppm. IR (HATR):
3279 (m, br), 2932 (w), 1702 (m), 1601 (m), 1542 (m), 1501 (w),
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1445 (m), 1318 (m), 1231 (m), 1143 (w), 1108 (m), 1086 (m), 1027
(s), 992 (s), 939 (m), 914 (w), 838 (w), 805 (w), 755 (w), 723 (w),
690 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 282.1 (M-glucoseþHþ, 100).
4-O-(N-Benzylcarbamoyl)-a,a-D-trehalose (23-e)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 10/0 to 7/3) afforded
the title compound 23-e as a white foam (99mg,
0.208mmol, 87%).
Rf 0.44 in CH3CN/H2O 8/2.
1H NMR (400MHz, CD3OD): d
7.32–7.27 (m, 4H), 7.25–7.19 (m, 1H), 5.14 (d, J¼ 3.8 Hz, 1H), 5.11
(d, J¼ 3.7 Hz, 1H), 4.58 (t, J¼ 9.8 Hz, 1H),4.30 (s, 2H), 4.00–3.91 (m,
2H), 3.84–3.74 (m, 3H), 3.70–3.45 (m, 5H), 3.32 (m, 1H) ppm. 13C
NMR (100MHz, CD3OD): d 158.9 (C), 140.5 (C), 129.5 (CH), 128.3
(CH), 128.2 (CH), 95.1 (CH), 94.8 (CH), 74.5 (CH), 73.8 (CH), 73.8
(CH), 73.4 (CH), 73.1 (CH), 72.1 (CH), 71.9 (CH), 62.6 (CH2), 62.4
(CH2), 45.6 (CH2) ppm. IR (HATR): 3311 (m, br), 2931 (w), 1698 (m),
1539 (w), 1454 (w), 1339 (w), 1254 (m), 1207 (w), 1145 (m), 1104
(w), 1080 (m), 1028 (m), 989 (s), 944 (m), 841 (w), 802 (w), 747 (w),
720 (w), 698 (m) cm1. [a]D
22 þ142 (c 0.10, MeOH). ESMS [m/z
(fragment, intensity), API-ES positive mode]: 476.2 (MþHþ, 100).
4-O-[N-(2-Phenethyl)carbamoyl]-a,a-D-trehalose (23-f)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 23-f as a white foam (112mg, 0.229mmol, 75%).
Rf 0.47 in CH3CN/H2O 8/2.
1H NMR (400MHz, CD3OD): d
7.30–7.14 (m, 5H), 5.14 (d, J¼ 3.8 Hz, 1H), 5.10 (d, J¼ 3.8 Hz, 1H),
4.57 (s, 1H), 4.58 (t, J¼ 9.6 Hz, 1H), 3.96–3.90 (m, 2H), 3.85–3.75 (m,
3H), 3.67 (dd, J¼ 12.0/6.5 Hz, 1H), 3.56 (dd, J¼ 9.9/3.8 Hz, 2H),
3.35–3.45 (m, 2H), 3.40–3.27 (m, 2H), 2.85–2.72 (m, 2H) ppm. 13C
NMR (100MHz, CD3OD): d 158.7 (C), 140.5 (C), 129.9 (CH), 129.5
(CH), 127.4 (CH), 95.1 (CH), 94.8 (CH), 74.5 (CH), 73.9 (CH), 73.6
(CH), 73.4 (CH), 73.1 (CH), 72.4 (CH), 72.0 (CH), 71.9 (CH), 62.6
(CH2), 62.4 (CH2), 43.5 (CH2), 37.0 (CH2) ppm. IR (HATR): 3320 (m,
br), 2931 (w), 1699 (m), 1540 (m), 1452 (w), 1339 (w), 1251 (m),
1202 (w), 1148 (m), 1106 (w), 1080 (m), 1030 (m), 989 (s), 846 (w),
806 (w), 748 (w), 698 (m) cm1. [a]D
22 þ132 (c 0.10, MeOH).
ESMS [m/z (fragment, intensity), API-ES positive mode]: 490.2
(MþHþ, 20), 310.0 (M-glucoseþHþ, 100).
4-O-(N-n-Octylcarbamoyl)-a,a-D-trehalose (23-g)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 10/0 to 7/3) afforded
the title compound 23-g as a white foam (154mg,
0.310mmol, 74%).
Rf 0.27 in CH3CN/H2O 8/2.
1H NMR (400MHz, CD3OD): d 5.14
(d, J¼ 3.9 Hz, 1H), 5.10 (d, J¼ 3.7 Hz, 1H), 4.53 (t, J¼ 9.8 Hz, 1H),
3.98 (m, 2H), 3.84–3.74 (m, 2H), 3.66 (dd, J¼ 12.0/5.5 Hz, 1H),
3.62–3.50 (m, 3H), 3.47 (dd, J¼ 9.6/3.7 Hz, 1H), 3.31 (m, 1H), 3.10
(t, J¼ 7.0 Hz, 2H), 3.09 (t, J¼ 7.2 Hz, 2H), 1–55-1.45 (m, 2H),
1.35–1.25 (m, 10H), 0.89 (t, J¼ 6.7 Hz, 3H) ppm. 13C NMR
(100MHz, CD3OD): d 158.8 (C), 95.1 (CH), 94.8 (CH), 74.5 (CH), 73.8
(CH), 73.5 (CH), 73.4 (CH), 73.1 (CH), 72.4 (CH), 72.1 (CH), 71.9 (CH),
62.6 (CH2), 62.4 (CH2), 41.9 (CH2), 33.0 (CH2), 30.9 (CH2), 30.4 (CH2),
30.4 (CH2), 27.9 (CH2), 23.7 (CH2), 14.4 (CH) ppm. IR (HATR): 3320
(m, br), 2928 (m), 2854 (w), 1697 (m), 1534 (m), 1456 (w), 1376
(w), 1257 (m), 1148 (m), 1104 (m), 1080 (m), 1027 (m), 992 (s), 944
(m), 846 (w), 804 (w) cm1. [a]D
22 þ157 (c 0.12, MeOH). ESMS [m/
z (fragment, intensity), API-ES negative mode]: 556.2
(MþOAc-, 100).
2,3,4,2’,3’,4’-Hexa-O-benzyl-6,6’-di-O-methyl-a,a-D-trehalose (24)
General procedure A was applied (use of iodomethane).
Purification via column chromatography (eluent: hexane/EtOAc 7/
3) afforded the title compound 24 as a colourless glass (482mg,
0.529mmol, 99%).
Rf 0.18 in hexane/EtOAc 7/3. 1H NMR (300MHz, CDCl3): d
7.40–7.22 (m, 30H), 5.19 (d, J¼ 3.6 Hz, 2H), 4.99 (d, J¼ 10.9 Hz, 2H),
4.87 (d, J¼ 11.1Hz, 2H), 4.85 (d, J¼ 10.9Hz, 2H), 4.70 (d,
J¼ 12.4 Hz, 2H, A-part of AB-system), 4.66 (d, J¼ 12.2Hz, 2H, B-
part of AB-system), 4.13 (app dt, J¼ 10.0/2.1 Hz, 2H), 4.02 (app t,
J¼ 9.3 Hz, 2H), 3.64 (app t, J¼ 9.6 Hz, 2H), 3.56 (dd, J¼ 9.7/3.7 Hz,
2H), 3.42 (dd, J¼ 10.6/2.8 Hz, 2H), 3.32–3.24 (m, 2H), 3.26 (s, 6H)
ppm. 13C NMR (100MHz, CDCl3): d 138.9 (C), 138.4 (C), 138.2 (C),
128.4 (CH), 128.3 (CH), 128.0 (CH), 127.8 (CH), 127.7 (CH), 127.5
(CH), 127.5 (CH), 94.7 (CH), 81.7 (CH), 79.3 (CH), 77.6 (CH), 75.5
(CH2), 75.1 (CH2), 72.7 (CH2), 70.6 (CH2), 70.5 (CH), 59.1 (CH3) ppm.
IR (HATR): 3027 (w), 2918 (w), 2882 (w), 1727 (w), 1496 (w), 1453
(m), 1359 (m), 1326 (w), 1267 (w), 1198 (m), 1149 (m), 1135 (m),
1090 (s), 1067 (s), 1027 (m), 992 (s), 915 (m), 848 (w), 802 (w), 734
(m), 695 (s), 642 (w) cm1. ESMS [m/z (fragment, intensity), API-ES
positive mode]: 928.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C56H66NO11
þ [MþNH4]þ 928.4630; found 928.4626.
6,6’-Di-O-methyl-a,a-D-trehalose (25)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 25 as a white solid (164mg, 0.443mmol, 92%).
Rf 0.31 in CH3CN/H2O 8/2, 0.29 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.05 (d, J¼ 3.7 Hz, 2H), 3.94 (ddd, J¼ 10.0/
4.7/2.6 Hz, 2H), 3.76 (app t, J¼ 9.3 Hz, 2H), 3.66–3.53 (m, 4H), 3.45
(dd, J¼ 9.8/3.8 Hz, 2H), 3.37 (s, 6H), 3.34–3.27 (m, 2H) ppm. 13C
NMR (100MHz, CD3OD): d 95.3 (CH), 74.5 (CH), 73.1 (CH), 73.0
(CH2), 72.5 (CH), 72.0 (CH), 59.5 (CH3) ppm. IR (HATR): 3300 (m, br),
2929 (w), 1454 (w), 1379 (w), 1334 (w), 1275 (w), 1241 (w), 1195
(w), 1148 (m), 1108 (m), 1079 (m), 1038 (m), 1015 (m), 986 (s), 944
(m), 911 (m), 856 (w), 808 (w), 688 (w) cm1. [a]D
22 þ190 (c 0.10,
MeOH). ESMS [m/z (fragment, intensity), API-ES positive mode]:
388.2 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C14H26NaO11þ
[MþNa]þ 393.1367; found 393.1360.
2,3,4,2’,3’,4’-Hexa-O-benzyl-6,6’-di-O-[N-(2-phenethyl)carbamoyl]-
a,a-D-trehalose (26)
General procedure B was applied (use of phenethyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 85/15 to 6/4) afforded the partially purified title compound
26 as a colourless glass which is used as such in the next step.
Rf 0.11 in hexane/EtOAc 7/3.
6,6’-Di-O-[N-(2-phenethyl)carbamoyl]-a,a-D-trehalose (27)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 6/4) afforded the
title compound 27 as a white solid (178mg, 0.280mmol, 65%
over 2 steps).
Rf 0.52 in CH3CN/H2O 8/2, 0.34 in CH2Cl2/MeOH 8/2.
1H NMR
(400MHz, CD3OD): d 7.30–7.10 (m, 10H), 5.13–4.99 (m, 2H),
4.37–4.14 (m, 4H), 4.09–3.92 (m, 2H), 3.77 (t, J¼ 9.3 Hz, 2H), 3.44
(br dd, J¼ 9.6/3.4 Hz, 2H), 3.37–3.23 (m, 6H), 2.76 (t, J¼ 7.4 Hz, 4H)
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ppm. 13C NMR (100MHz, CD3OD): d 159.1 (C), 140.5 (C), 129.8
(CH), 129.5 (CH), 127.3 (CH), 95.3 (CH), 74.5 (CH), 73.2 (CH), 71.9
(CH), 71.8 (CH), 64.9 (CH2), 43.5 (CH2), 37.1 (CH2) ppm. IR (HATR):
3342 (m, br), 2934 (w), 1697 (s), 1520 (m), 1496 (w), 1454 (w),
1347 (w), 1327 (w), 1240 (m), 1204 (w), 1148 (m), 1099 (m), 1074
(m), 1040 (m), 1015 (m), 984 (s), 942 (m), 909 (w), 853 (w), 808 (w),
772 (w), 749 (w), 698 (m) cm1. [a]D
22 þ110 (c 0.10, MeOH).
ESMS [m/z (fragment, intensity), API-ES negative mode]: 637.2
(MþHþ, 100). HRMS (ESI-TOF): calcd. for C30H40N2NaO13 [MþNa]þ
659.2423; found 629.2414.
2,3,6,2’,3’,6’-Hexa-O-benzyl-4,4’-di-O-methyl-a,a-D-trehalose (28)
General procedure A was applied (use of iodomethane).
Purification via column chromatography (eluent: hexane/EtOAc 8/
2) afforded the title compound 28 as a colourless glass (302mg,
0.331mmol, 98%).
Rf 0.21 in hexane/EtOAc 8/2. 1H NMR (400MHz, CDCl3): d
7.43–7.22 (m, 30H), 5.19 (d, J¼ 3.5 Hz, 2H), 4.97 (d, J¼ 10.9 Hz, 2H),
4.86 (d, J¼ 10.9Hz, 2H), 4.69 (d, J¼ 12.1 Hz, 2H, A-part of AB-sys-
tem), 4.67 (d, J¼ 12.2Hz, 2H, B-part of AB-system), 4.58 (d,
J¼ 12.1Hz, 2H), 4.43 (d, J¼ 12.1Hz, 2H), 4.09 (app dt, J¼ 10.1/
2.3 Hz, 2H), 3.94 (app t, J¼ 9.3 Hz, 2H), 3.57–3.36 (m, 8H), 3.47 (s,
6H) ppm. 13C NMR (100MHz, CDCl3): d 138.9 (C), 138.2 (C), 138.0
(C), 128.3 (CH), 128.3 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.6
(CH), 127.5 (CH), 127.4 (CH), 94.6 (CH), 81.7 (CH), 79.3 (CH), 79.2
(CH), 75.5 (CH2), 73.4 (CH2), 72.7 (CH2), 70.6 (CH), 68.2 (CH2), 60.6
(CH3) ppm. IR (HATR): 3064 (w), 3028 (w), 2930 (w), 2859 (w), 1496
(w), 1453 (m), 1364 (m), 1331 (w), 1207 (w), 1155 (m), 1135 (m),
1090 (s), 1024 (m), 993 (s), 913 (m), 854 (w), 797 (w), 732 (s), 695
(s), 636 (w) cm1. ESMS [m/z (fragment, intensity), API-ES positive
mode]: 928.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for
C56H66NO11
þ [MþNH4]þ 928.4630; found 928.4639.
4,4’-Di-O-methyl-a,a-D-trehalose (29)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 29 as a white solid (99mg, 0.267mmol, 86%).
Rf 0.28 in CH3CN/H2O 8/2, 0.31 in CH2Cl2/MeOH 7/3.
1H NMR
(400MHz, CD3OD): d 5.06 (d, J¼ 3.8 Hz, 2H), 3.85 (app t, J¼ 9.4 Hz,
2H), 3.79 (ddd, J¼ 10.0/4.3/2.0 Hz, 2H), 3.74 (dd, J¼ 11.8/2.1 Hz,
2H), 3.65 (dd, J¼ 11.9/4.5 Hz, 2H), 3.55 (s, 6H), 3.45 (dd, J¼ 9.8/
3.8 Hz, 2H), 3.11 (dd, J¼ 9.7/9.2 Hz, 2H) ppm. 13C NMR (100MHz,
CD3OD): d 95.0 (CH), 81.1 (CH), 74.5 (CH), 73.3 (CH), 72.8 (CH), 62.1
(CH2), 60.8 (CH3) ppm. IR (HATR): 3380 (m, br), 2932 (w), 1660 (w),
1472 (w), 1442 (w), 1420 (w), 1389 (w), 1339 (w), 1317 (w), 1244
(w), 1229 (w), 1209 (w), 1192 (w), 1156 (m), 1135 (m), 1101 (m),
1063 (s), 1029 (m), 992 (s), 963 (s), 928 (m), 854 (m), 804 (w), 702
(w), 655 (w) cm1. [a]D
22 þ220 (c 0.10, MeOH). ESMS [m/z (frag-
ment, intensity), API-ES positive mode]: 393.1 (MþNaþ, 41), 388.2
(MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C14H26NaO11þ
[MþNa]þ 393.1367; found 393.1361.
2,3,2’,3’,4’,6’-Hexa-O-benzyl-4,6’-di-O-methyl-a,a-D-trehalose (30)
General procedure A was applied (use of iodomethane).
Purification via column chromatography (gradient elution: hexane/
EtOAc 85/15 to 75/25) afforded the title compound 30 as a col-
ourless oil (131mg, 0.144mmol, 85%).
Rf 0.12 in hexane/EtOAc 8/2. 1H NMR (400MHz, CDCl3): d
7.40–7.18 (m, 28H), 7.16–7.08 (m, 2H), 5.20 (d, J¼ 3.5 Hz, 1H), 5.17
(d, J¼ 3.7 Hz, 1H), 4.99 (d, J¼ 11.0 Hz, 1H), 4.95 (d, J¼ 11.0 Hz, 1H),
4.85 (app d, J¼ 10.9 Hz, 2H), 4.80 (d, J¼ 10.7 Hz, 1H), 4.71–4.60 (m,
4H), 4.54 (d, J¼ 12.1Hz, 1H), 4.45 (d, J¼ 10.8Hz, 1H), 4.36 (d,
J¼ 12.2 Hz, 1H), 4.16 (dt, J¼ 9.9/2.2 Hz, 1H), 4.05 (dt, J¼ 10.1/
2.4 Hz, 1H), 4.02 (app t, J¼ 9.5 Hz, 1H), 3.91 (app t, J¼ 9.3 Hz, 1H),
3.68 (app br t, J¼ 9.6 Hz, 1H), 3.59 (dd, J¼ 9.6/3.5 Hz, 1H),
3.54–3.28 (m, 6H), 3.53 (s, 3H), 3.32 (s, 3H) ppm. 13C NMR
(100MHz, CDCl3): d 139.0 (C), 138.9 (C), 138.4 (C), 138.3 (C), 138.2
(C), 137.8 (C), 128.4 (CH), 128.3 (CH), 128.3 (CH), 128.3 (CH), 128.0
(CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 127.6 (CH),
127.5 (CH), 127.4 (CH), 127.4 (CH), 94.7 (CH), 94.7 (CH), 81.8 (CH),
81.5 (CH), 79.4 (CH), 79.3 (CH), 79.1 (CH), 77.6 (CH), 75.6 (CH2), 75.4
(CH2), 75.1 (CH2), 73.5 (CH2), 72.7 (CH2), 70.7 (CH2), 70.6 (CH), 70.5
(CH), 68.1 (CH2), 60.5 (CH3), 59.1 (CH3) ppm. IR (HATR): 3059 (w),
3028 (w), 2915 (w), 2868 (w), 1496 (w), 1453 (m), 1363 (m), 1328
(w), 1265 (w), 1199 (w), 1153 (m), 1140 (m), 1087 (s), 1069 (s),
1026 (m), 992 (s), 920 (m), 853 (w), 799 (w), 733 (s), 695 (s), 638
(w) cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
928.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C56H66NO11þ
[MþNH4]þ 928.4630; found 928.4645.
4,6-Di-O-methyl-a,a-D-trehalose (31)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 31 as a white glass (42.8mg, 0.116mmol, 87%).
Rf 0.29 in CH3CN/H2O 8/2, 0.16 in CH2Cl2/MeOH 8/2.
1H NMR
(400MHz, CD3OD): d 5.07 (d, J¼ 3.8 Hz, 1H), 5.05 (d, J¼ 3.8 Hz, 1H),
3.91 (ddd, J¼ 10.0/4.2/2.1 Hz, 1H), 3.85 (app t, J¼ 9.4 Hz, 1H),
3.82–3.72 (m, 3H), 3.66 (dd, J¼ 12.0/5.5 Hz, 1H), 3.62–3.52 (m, 2H),
3.53 (s, 3H), 3.47 (dd, J¼ 9.8/3.8 Hz, 1H), 3.45 (dd, 9.8/3.7 Hz, 1H),
3.38 (s, 3H), 3.35–3.27 (m, 1H), 3.09 (dd, J¼ 10.0/9.0 Hz, 1H) ppm.
13C NMR (100MHz, CD3OD): d 95.2 (CH), 95.0 (CH), 81.3 (CH), 74.5
(CH), 74.4 (CH), 73.8 (CH), 73.3 (CH), 73.2 (CH), 72.6 (CH2), 71.8
(CH), 71.5 (CH), 62.6 (CH2), 60.8 (CH3), 59.4 (CH3) ppm. IR (HATR):
3338 (m, br), 2922 (w), 1373 (m, br), 1192 (w), 1069 (m), 1032 (m),
989 (s), 968 (m), 936 (m), 924 (m), 912 (m), 802 (m), 681 (w) cm1.
[a]D
22 þ203 (c 0.10, MeOH). ESMS [m/z (fragment, intensity), API-
ES positive mode]: 388.2 (MþNH4þ, 100). HRMS (ESI-TOF): calcd.
for C14H26NaO11 [MþNa]þ 393.1367; found 393.1359.
2,3,4,2’,3’,4’-Hexa-O-benzyl-6-O-methyl-a,a-D-trehalose (32)
To a cooled (0 C) solution of 16-a (420mg, 0.469mmol, 1 eq) in
toluene (5ml), DIBAL-H (supplied as 1.0M solution in toluene,
2.35ml, 2.35mmol, 5 eq) was added dropwise. After 15min, the
cooling bath was removed and the reaction mixture was stirred
for 48 h. The resulting solution was cooled to 0 C after which
MeOH (1.3ml) and 10% aqueous KOH (0.4ml) were added. The
mixture was transferred to a separation funnel using H2O (35ml)
and dichloromethane (35ml). The organic layer was separated and
the aqueous layer was extracted with dichloromethane (3 35ml).
The combined organic layers were washed with brine (50ml) and
concentrated under reduced pressure. The residue was purified
via column chromatography (gradient elution: hexane/EtOAc 7/3
to 6/4), giving the title compound 32 as a colourless glass in 76%
yield (277mg, 0.3088mmol) based on recovered starting mater-
ial (55mg).
Rf 0.12 in hexane/EtOAc 6/4. 1H NMR (400MHz, CDCl3): d
7.40–7.23 (m, 30H), 5.18 (d, J¼ 3.5 Hz, 1H), 5.15 (d, J¼ 3.7 Hz, 1H),
5.00 (d, J¼ 10.9 Hz, 1H), 4.99 (d, J¼ 10.9 Hz, 1H), 4.92–4.83 (m, 4H),
4.76–4.62 (m, 5H), 4.58 (d, J¼ 11.0 Hz, 1H), 4.18–3.98 (m, 4H),
3.69–3.49 (m, 6H), 3.42 (br dd, J¼ 10.6/3.1 Hz, 1H), 3.31 (br dd,
J¼ 10.6/2.0 Hz, 1H), 3.27 (s, 3H), 1.46 (br t, J¼ 6.0 Hz, 1H) ppm. 13C
NMR (100MHz, CDCl3): d 138.9 (C), 138.8 (C), 138.4 (C), 138.2 (C),
138.2 (C), 138.1 (C), 128.5 (CH), 128.4 (CH), 128.4 (CH), 128.4 (CH),
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128.3 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7
(CH), 127.6 (CH), 127.6 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH),
94.4 (CH), 94.2 (CH), 81.7 (CH), 81.6 (CH), 79.5 (CH), 79.3 (CH), 77.6
(CH), 75.6 (CH2), 75.5 (CH2), 75.1 (CH2), 75.1 (CH2), 72.9 (CH2), 72.8
(CH2), 71.2 (CH), 70.7 (CH2), 70.6 (CH), 61.5 (CH2), 59.1 (CH3) ppm.
IR (HATR): 3479 (w, br), 3059 (w), 3029 (w), 2920 (w), 2873 (w),
1496 (w), 1453 (m), 1396 (w), 1359 (m), 1328 (w), 1208 (w), 1153
(m), 1133 (m), 1088 (s), 1068 (s), 1027 (m), 990 (s), 920 (m), 847
(w), 798 (w), 732 (s), 695 (s), 641 (w) cm1. ESMS [m/z (fragment,
intensity), API-ES positive mode]: 914.4 (MþNH4þ, 100). HRMS




General procedure B was applied (use of phenethyl isocyanate).
Purification via column chromatography (gradient elution: hexane/
EtOAc 8/2 to 6/4) afforded the title compound 33 as a colourless
glass (280mg, 0.268mmol, 98%).
Rf 0.13 in hexane/EtOAc 7/3. 1H NMR (400MHz, CDCl3): d
7.40–7.10 (m, 35H), 5.19 (d, J¼ 3.4 Hz, 1H), 5.15 (d, J¼ 3.4 Hz, 1H),
5.01 (d, J¼ 11.2Hz, 1H), 4.98 (d, J¼ 11.6 Hz, 1H), 4.92–4.77 (m, 4H),
4.73–4.49 (m, 7H), 4.31–3.95 (m, 6H), 3.68–3.25 (m, 8H), 3.27 (s,
3H), 2.75 (t, J¼ 7.0 Hz, 2H) ppm. 13C NMR (100MHz, CDCl3): d
155.9 (C), 138.9 (C), 138.7 (C), 138.6 (C), 138.4 (C), 138.1 (C), 137.9
(C), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.4 (CH), 128.4
(CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH),
127.7 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 126.5 (CH), 94.7
(CH), 94.3 (CH), 81.7 (CH), 81.6 (CH), 79.3 (CH), 79.1 (CH), 75.6
(CH2), 75.5 (CH2), 75.1 (CH2), 72.9 (CH2), 72.7 (CH2), 70.6 (CH2), 70.6
(CH), 69.5 (CH), 63.1 (CH2), 59.1 (CH3), 42.1 (CH2), 36.0 (CH2) ppm.
IR (HATR): 3410 (w), 3341 (w), 3086 (w), 3059 (w), 3026 (w), 2920
(w), 2877 (w), 1722 (m), 1514 (w), 1496 (m), 1454 (m), 1401 (w),
1359 (w), 1328 (w), 1242 (m), 1208 (w), 1153 (m), 1086 (m), 1068
(s), 1027 (m), 991 (s), 911 (w), 850 (w), 797 (w), 733 (s), 695 (s), 640
(w) cm1. ESMS [m/z (fragment, intensity), API-ES positive mode]:
1061.4 (MþNH4þ, 100). HRMS (ESI-TOF): calcd. for C64H73N2O12
[MþNH4]þ 1061.5158; found 1061.5179.
6-O-Methyl-6’-O-[N-(2-Phenethyl)carbamoyl]-a,a-D-trehalose (34)
General procedure C was applied. Purification via column chroma-
tography (gradient elution: CH2Cl2/MeOH 9/1 to 7/3) afforded the
title compound 34 as a white glass (96mg, 0.191mmol, 83%).
Rf 0.49 in CH3CN/H2O 8/2, 0.17 in CH2Cl2/MeOH 8/2.
1H NMR
(400MHz, CD3OD): d 7.32–7.13 (m, 5H), 5.14–4.99 (m, 2H),
4.36–4.14 (m, 2H), 4.08–3.88 (m, 2H), 3.83–3.71 (m, 2H), 3.66–3.52
(m, 2H), 3.51–3.40 (m, 2H), 3.37 (s, 3H), 3.35–3.26 (m, 4H), 2.77 (t,
J¼ 7.4 Hz, 2H) ppm. 13C NMR (100MHz, CD3OD): d 159.1 (C), 140.5
(C), 129.8 (CH), 129.5 (CH), 127.3 (CH), 95.3 (CH), 74.5 (CH), 74.5
(CH), 73.1 (CH), 73.1 (CH2), 72.5 (CH), 72.0 (CH), 71.8 (CH), 64.9
(CH2), 59.5 (CH3), 43.5 (CH2), 37.1 (CH2) ppm. IR (HATR): 3308 (m,
br), 2926 (w), 1697 (m), 1526 (w), 1496 (w), 1455 (w), 1334 (w),
1252 (m), 1197 (w), 1146 (m), 1101 (m), 1074 (m), 1037 (m), 1018
(m), 987 (s), 943 (m), 909 (w), 856 (w), 807 (w), 772 (w), 750 (w),
700 (w) cm1. [a]D
22 þ132 (c 0.10, MeOH). ESMS [m/z (fragment,
intensity), API-ES positive mode]: 504.2 (MþHþ, 100). HRMS (ESI-
TOF): calcd. for C22H33NNaO12 [MþNa]þ 526.1895;
found 526.1879.
Scheme 1. Synthesis of strategic intermediates. Reagents and conditions: (a) 2.3 eq benzaldehyde dimethyl acetal, 0.05 eq camphorsulfonic acid, DMF, 95 C, 30min;
(b) 10 eq NaH, 8 eq BnBr, 0.2 eq TBAI, DMF, 0 C-rt, 18 h; (c) 5 eq DIBAL-H, toluene, 18 C-rt, 2 h; (d) 5 eq DIBAL-H, CH2Cl2, 0 C-rt, 90min; (e) 5 eq DIBAL-H, toluene,
48 h; (f) 2.5 eq NaH, 4 eq BnBr, DMF, 16 h; (g) 12 eq Me3N-BH3, 12 eq AlCl3, THF, molecular sieves (4 Å), 16 h; (h) 1 eq benzaldehyde dimethyl acetal, 0.05 eq camphor-
sulfonic acid, DMF, 90 C, 15min; (i) Ac2O/pyridine 1/1, 24 h; (j) 12 eq NaOMe, MeOH, 1 h; (k) 15 eq NaH, 12 eq BnBr, 0.2 eq TBAI, 0 C-rt, 16 h; (l) TFA/CH2Cl2/MeOH 1/
3/9, 120 h.
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Enzyme activity assays
Trehalose and each derivative (20mM) were incubated with
0.01mg ml1 trehalase from porcine kidney (Sigma Aldrich) or
Mycobacterium smegmatis (NZYtech) in 100mM of sodium phos-
phate buffer (pH 7) at 37 C for 24 h. Mixtures with Mycobacterium
smegmatis trehalase also contained 6mM of MgSO4, as the
enzyme requires Mg2þ for activity32. Samples were taken at regu-
lar time intervals and diluted with ultrapure water for analysis
with high performance anion-exchange chromatography with
pulsed amperometric detection (HPAEC-PAD, Dionex ICS-3000).
In order to evaluate their relative inhibition percentage, each
trehalose derivative (20mM) was incubated with 0.01mg ml1 of
above-mentioned trehalases with 3 or 20mM of trehalose for por-
cine kidney and Mycobacterium smegmatis trehalases, respectively,
in 100mM of sodium phosphate buffer (pH 7) at 37 C for 14min.
Again, 6mM of MgSO4 was added to the reaction mixture with
Mycobacterium smegmatis trehalase. Samples were taken every
2min and diluted with ultrapure water for analysis with HPAEC-
PAD. The residual activity of the enzyme towards trehalose in
each mixture was determined by comparing the measured activity
to the activity determined in the absence of trehalose derivative.
For selected compounds 2, 17-a, 19-d, 19-e, 19-f, 21-a, 23-f,
and 31, IC50 values were determined by incubating different con-
centrations of the trehalose derivative (0.01–50mM) with the
selected trehalases under the same conditions as mentioned
above. Samples were taken every 2min and diluted for analysis
with HPAEC-PAD. The residual activity of the enzyme towards tre-
halose in each mixture was determined compared to a sample
without trehalose derivative. Plots and curve fits were obtained
via Sigmaplot 13. All reactions were performed in triplicate, values
are represented as the mean and standard deviations were in the
range of 15% of the reported value.
Molecular modelling
All manipulations were performed with the molecular modelling
program YASARA and the YASARA/WHATIF twinset and figures
were created with PyMOL 2.0. The ligand free and inhibitor bound
crystal structures of trehalase from Enterobacter cloacae (GH37
family) (PDB code 5Z6H and 5Z66, respectively)33 were used as
template for docking. Trehalose derivative structures were created
with YASARA Structure and subsequently minimised with the
AMBER03 force field. The grid box for docking had a dimension of
25 25 25Å and comprised the entire catalytic cavity. Docking
was performed with AutoDock VINA using default parameters and
ligands were allowed to rotate freely during the simulation. The
conformer with an appropriate glucose in both the 1 and þ1
subsite was selected as the binding mode for further analysis.
Results
Chemistry
Synthesis of strategic intermediates
Generally, synthesis of all final analogues was achieved from a
central set of partially protected strategic intermediates 7–10, 12
and 15 which could be obtained from trehalose 1 (Scheme 1).
After protection of both 4- and 6-hydroxyl groups in trehalose as
benzylidene acetal, the remaining OH functional groups were con-
verted to the corresponding benzyl ethers, leading to 627. In the
following crucial desymmetrisation step, regioselective reductive
opening of one of the acetal moieties to either the 4- or 6-mono-
alcohol can be achieved using diisobutylaluminium hydride
(DIBAL-H) in an appropriate solvent, according to existing litera-
ture27. Based on reported conditions, selective opening towards
strategic intermediate 7 containing a free 6-OH group was
achieved through reaction in toluene. The alternative 4-OH isomer
8 could be obtained via DIBAL-H reduction in dichloromethane: in
a typical experiment, starting material still remained at moment of
quenching (10% recovered), while in addition to the desired com-
pound 8 (55%), regio-isomer 7 (19%) and product 9 (9%, resulting
from overreduction) were also isolated through tedious chromato-
graphic separation. Compound 9 was found to be useful as an
additional strategic intermediate to access 4/40-bis-substituted
derivatives; the corresponding 6/60-bis-OH intermediate 10 was
obtained after a second DIBAL-H treatment of 7 in toluene. To
avoid the above-mentioned practical issues concerning synthesis
of 8, we decided to additionally synthesise alternative strategic
intermediate 12, also allowing the subsequent synthesis of 4-sub-
stituted derivatives. This was achieved via sequential O-benzyla-
tion of 7 and opening of the resulting mono-benzylidene acetal
11 using Me3N-BH3/AlCl3
34. Under the latter conditions, the
desired 4-OH isomer 12 could be isolated in 49% yield, while the
fraction of corresponding 6-OH regio-isomer amounted to 38%
(compound not shown). Alternatively, intermediate 11 could be
obtained via the mono-benzylidene acetal-protected 13. Although
this was expected to involve a shorter reaction route from trehal-
ose, an extra acetylation/deacetylation sequence via 14 was found
to be necessary to facilitate intermediate purification, leading to
Scheme 2. Synthesis of 6-O-substituted trehalose derivatives. Reagents and conditions: (a) 2.5 eq NaH, 4 eq R-Br or R-I, DMF, 16 h; (b) 0.05 eq Pd/C, EtOAc/MeOH 1/1,
16 h; (c) 3 eq R-N¼ C¼O, 0.2 eq DMAP, CH2Cl2, 24–120 h.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1981
an equal number of reaction steps but significantly lower overall
yield. Finally, acid hydrolysis of the acetal moiety in 11 was used
to obtain 4/6-bis-OH strategic intermediate 15. With these stra-
tegic intermediates in hand, different sets of 4- or 6-monosubsti-
tuted, and 4/40-, 6/60- and 4/6-double substituted analogues were
accessible, via derivatisation of the remaining unprotected alco-
hol moieties.
Derivatisation of strategic intermediates to final compounds
First, using strategic intermediate 7, two series of 6-O-monosubsti-
tuted derivatives were prepared (Scheme 2). On one hand, O-alkyl-
ation using alk(en)yl halogenides with increasing chain length
under standard conditions delivered intermediates 16-a–g, which
were overall deprotected using catalytic hydrogenolysis to obtain
the intended 6-O-alkylated trehalose derivatives 17-a–g. On the
other hand, a series of 6-O-carbamoyl derivatives 19-a–g was pre-
pared via treatment of 7 with a set of isocyanates in presence of
DMAP, followed by hydrogenolysis.
Next, two analogous series of 4-O-substituted trehalose deriva-
tives were envisaged (Scheme 3). Indeed, alkylation of 8 using the
same set of alk(en)yl halogenides mentioned above gave the
expected ethers 20-a–g which were deprotected to the final
derivatives 21-a–g. Additionally, lentztrehalose A 2 was synthes-
ised following reported conditions, via Sharpless asymmetric dihy-
droxylation of 4-O-prenylated intermediate 20-f and subsequent
hydrogenolysis of 20-h30. From 1H-NMR analysis, a diastereomeric
excess of 73% 20-h could be determined (Figure S1 in
Supplementary Information). Both diastereomers could not be
separated chromatographically and the resulting lentztrehalose A
2 was therefore used as such for trehalase evaluation. In analogy
to the 6-O-series 19-a–g, we also prepared the corresponding 4-
O-carbamates 23-a-g in two steps from strategic intermediate 12.
Finally, a selection of double-substituted analogues was pre-
pared (Scheme 4). To this end, the appropriate bis-OH strategic
intermediates 10, 9 and 15 were reacted with MeI and subse-
quently deprotected to obtain the 6/60-, 4/40- and 4/6-bis-O-
methyl derivatives 25, 29 and 31, respectively. Additionally, 6/60-
bis-phenethylcarbamoyl trehalose 27 was obtained from 10.
Lastly, mixed derivative 34 was obtained via methylation of inter-
mediate 16-a, followed by regioselective acetal opening using
DIBAL-H in toluene, conversion to the carbamate 33 and final
debenzylation.
Biological evaluation
Resistance to trehalase hydrolytic activity
The hydrolytic resistance of each trehalose derivative was eval-
uated by incubating 20mM of substrate with 0.01mg ml1 of
enzyme at pH 7 and 37 C for 24 h. No degradation was observed
for the majority of derivatives, whereas trehalose was already bro-
ken down completely after just 12 h (data not shown). The only
exceptions showing significant hydrolysis were derivatives 17-a (7
and 8% relative hydrolysis by the trehalase from porcine kidney
and M. smegmatis, respectively), 17-b (1 and 6%, respectively) and
17-c (1% and 1%, respectively), which all contain a small alkyl
group (i.e. methyl, ethyl and n-propyl, respectively) on the 6-
O-position.
Inhibitory activity towards trehalase
The inhibitory activity of the compounds was evaluated at a con-
centration of 20mM, using trehalose as substrate at a concentra-
tion equal to the respective Michaelis–Menten constant (3mM
and 20mM for porcine kidney and M. smegmatis trehalase,
respectively). Despite their resistance to hydrolysis, several of
these compounds were found to still bind quite tightly to these
trehalases, causing enzyme inhibition (Table 1).
Regarding porcine kidney trehalase, the most interesting inhibi-
tors are grouped within the series of 6-O-substituted derivatives,
as their counterparts with 4-O-substitutions are all poor inhibitors
(35% inhibition at 20mM). Only two derivatives, namely 17-a
and 19-f, exhibited complete inhibition. However, these com-
pounds bear very different substituents in both size and chemical
properties, i.e. methyl ether and phenethyl carbamate, respect-
ively. Compared to 17-a, extension of the alkyl ether substituent
resulted in a clear drop in inhibition. Similar to compound 19-f,
the other phenyl group-containing carbamates, 19-d and 19-e,
exhibited significant inhibitory effects (>80%). Compounds in the
carbamate series devoid of a phenyl moiety, i.e. 19-a, 19-b, 19-c
and 19-g, showed a clearly lowered inhibition, suggesting that
the aromatic group forms a crucial interaction with the enzyme.
Interestingly, compared to 17-a and 19-f, the additional introduc-
tion of either of their substituents on the 60-O-position, i.e. leading
to 25, 27 and 34, led to a lower rather than a higher affinity.
Likewise, the introduction of an additional methyl substituent on
the 4-O-position in 31 led to a similar lowered inhib-
ition outcome.
Scheme 3. Synthesis of 4-O-substituted trehalose derivatives. Reagents and conditions: (a) 2.5 eq NaH, 4 eq R-Br or R-I, DMF, 16 h; (b) AD-mix a, 2.5 eq MeSO2NH2,
0.25 eq (DHQ)2PHAL, tBuOH/H2O:acetone 1/1/0.9, 240 h; (c) 0.05 eq Pd/C, EtOAc/MeOH 1/1, 16 h; (d) 3 eq R-N¼ C¼O, 0.2 eq DMAP, CH2Cl2, 24–120 h.
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Towards M. smegmatis trehalase, contrarily, members of both
series of 4- and 6-O-substituted compounds generally demon-
strated interesting inhibitory properties at a concentration of
20mM. Whereas high inhibition is observed for 6-O-alkyl deriva-
tives (in contrast to the somewhat lower activity of the
corresponding 4-O-alkyl analogues), carbamate derivatives bearing
a cyclohexyl, phenyl, benzyl or phenethyl group on either the 4-
or 6-O-position (19-c-f, 23-c-f) all cause a high to complete inhib-
ition. Furthermore, all 4,40-, 6,60- and 4,6-bis-substituted derivatives
show an inhibition percentage that exceeds 90%. Compounds
Scheme 4. Synthesis of double-substituted trehalose derivatives. Reagents and conditions: (a) 5 eq NaH, DMF, 0 C, 15min; then: 8 eq MeI, DMF, 0 C-rt, 16 h; (b) 0.05
eq Pd/C, EtOAc/MeOH 1/1, 16 h; (c) 6 eq 2-phenethyl isocyanate, 0.4 eq DMAP, CH2Cl2, 48 h; (d) 5 eq DIBAL-H, toluene, 48 h; (e) 3 eq 2-phenethyl isocyanate, 0.2 eq
DMAP, CH2Cl2, 72 h.
Table 1. Inhibition (%) of porcine kidney trehalase (3mM trehalose) and M. smegmatis trehalase (20mM trehalose) in the presence of 4- (left) and 6-O-substituted
(right) derivatives of trehalose (20mM).
Substituent
4-position 6-position
Cpd Porcine kidney (%)a M. smegmatis (%)a Cpd Porcine kidney (%)a M. smegmatis (%)a
-O(CH2)2OHCH(CH3)2OH 2 1 100 (93
b) – – –
-OCH3 21-a 20 90 17-a 100 (4
b) 100 (76b)
-OCH2CH3 21-b 7 82 17-b 45 94
-O(CH2)2CH3 21-c 3 88 17-c 47 82
-O(CH2)3CH3 21-d 35 31 17-d 36 84
-OCH2CH(CH3)2 21-e 0 40 17-e 24 95
-O(CH2)2CH(CH3)2 21-f 0 10 17-f 7 96
-O(CH2)9CH3 21-g 0 0 17-g 28 0
-OC(¼O)NH(CH2)2CH3 23-a 0 24 19-a 23 83
-OC(¼O)NHCH2(CH3)2 23-b 0 44 19-b 17 67
-OC(¼O)NHCy 23-c 0 100 (38b) 19-c 5 78
-OC(¼O)NHPh 23-d 32 100 (51b) 19-d 83 100 (44b)
-OC(¼O)NHCH2Ph 23-e 18 87 19-e 90 100 (47b)
-OC(¼O)NH(CH2)2Ph 23-f 8 93 19-f 100 (12b) 100 (74b)
-OC(¼O)NH(CH2)7CH3 23-g 0 0 19-g 26 0
4,40-bis-OCH3 29 10 100 (43
b) – – –
6,60-bis-OCH3 – – – 25 47 91
4,6-bis-OCH3 31 16 100 (88
b) 31 16 100 (88b)
6,60-bis-OOCNH(CH2)2Ph – – – 27 0 100 (42
b)
6-OCH3,60-OC(¼O)NH(CH2)2Ph – – – 34 7 98
aMean from three different assays, analysis with HPAEC-PAD (errors were in the range of 15% of the reported value).
b% Inhibition at inhibitor concentration of 1mM.
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with longer (n-octyl/n-decyl) hydrophobic chains at the 4- or 6-O-
positions (17-g, 19-g, 21-g and 23-g), resulted in a lack of inhibi-
tory effect towards M. smegmatis trehalase.
To further rank the derivatives that caused complete inhibition,
the abovementioned experiments were repeated with a lower
inhibitor concentration, i.e. 1mM instead of 20mM (Table 1).
Additionally, eight trehalose derivatives were also subjected to
half maximal inhibitory concentration (IC50) experiments (Table 2).
This confirmed that compounds 17-a and 19-f are the strongest
inhibitors for porcine kidney trehalase, while derivatives 2, 17-a,
19-f and 31 displayed sub-mM IC50 values against M. smegmatis
trehalase. Interestingly, the IC50 of the strongest inhibitors of por-
cine kidney trehalase is about 10mM whereas substantially lower
values (down to 0.35mM) are found for the M. smegma-
tis trehalase.
Molecular docking studies
To clarify the displayed activities of the new derivatives, molecular
docking studies were carried out. Unfortunately, no structural elu-
cidation was possible for the enzyme from M. smegmatis as no
crystal structure of a trehalase from family GH15 has yet been
determined. However, several crystal structures of trehalases from
family GH37 are described in literature, namely from Escherichia
coli, Saccharomyces cerevisiae and Enterobacter cloacae33,35–37.
Interestingly, the latter has been crystallised in two different
forms, i.e. with and without the inhibitor validoxylamine A 36,
which resulted in structures that can be described as ‘closed’ and
‘open’, respectively. Indeed, the so-called lid loop (G506-G519) and
side loop (Y147-Y159) were found to undergo a significant conform-
ational change upon ligand binding (Figure 2)33. Docking simula-
tions were performed with these structures as representative
scenario for family GH37 trehalases, such as the one from porcine
kidney. The bacterial enzyme shares about 30% sequence identity
and 40% similarity with porcine and human trehalase, but all
active site residues within a distance of 4 Å from validoxylamine A
36 are fully conserved (Supplementary Figure S2). It was hypoth-
esised that a compound sensitive to hydrolysis should find a pro-
ductive docking pose in both the open and closed conformation,
whereas a hydrolysis-resistant inhibitor should only be accommo-
dated by the former.
After removal of the cocrystallised validoxylamine A 36, trehal-
ose 1 was docked in the active site pocket of the closed structure
and compared with the reference compound 36 (Figure 2, bot-
tom). A very good overlay was observed after superposition, with
most of the crucial interactions being conserved. A similar result
was obtained after docking of trehalose 1 and validoxylamine A
36 in the open structure (Figure 2, top). Subsequently, the binding
of various trehalose derivatives was simulated (Figure 3; Table 3).
Compound 21-a (4-O-methyltrehalose) was picked as a 4-O-
substituted representative in order to find an explanation for their
low inhibitory activity and high resistance to hydrolysis. In the
open form, two docking poses were found, i.e. with the methyl
substituent positioned in either subsite 1 or þ1. However, nei-
ther of these fits match with the one of trehalose, and very little
interactions are formed between enzyme and ligand (Figure 3).
There obviously is little space around the 4-hydroxy position of
trehalose in both subsite 1 and þ1 (Figure 2), explaining why
the bulkier compounds cannot take on the same pose as trehal-
ose. Furthermore, no productive docking result could be obtained
in the closed structure.
In contrast to their 4-O-substituted counterparts, 6-O-substi-
tuted derivatives show a far more interesting inhibitory profile. A
distinction can be made between the ether and carbamate deriva-
tives. For example, the 6-methoxy derivative 17-a triggered minor
hydrolytic activity as well as an attractive inhibitory effect.
Docking simulations confirmed our hypothesis that the derivative
could find a productive conformation in both the open and closed
structure (Figure 3). Interestingly, the substitution is accommo-
dated in subsite 1 rather than þ1, although the latter seems to
offer more space (Figure 2). In contrast, substitutions containing
four or more carbons are preferentially positioned in subsite þ1,
although their inhibitory potential is considerably lower. These
findings suggest that a greater affinity can be achieved when the
substituent is sufficiently small to be placed in subsite 1.
A trend could be noticed within the 6-O-carbamate derivatives,
as the inhibitory potential among these compounds clearly is
highest when a phenyl group is present. For instance, complete
inhibition of porcine kidney trehalase without hydrolysis was
observed with compound 19-f, containing a N-phenethylcarba-
moyl group. This trehalose derivative was able to find a fit in the
open active site (Figure 3), while its positioning in the closed
structure was predicted to have a negative binding energy (i.e.
repulsion, Table 3). A strong stacking interaction is established
between the compound’s aromatic group and F154, and again, the
substituent was found to be accommodated in subsite 1.
Docking simulations were also performed with both other phenyl-
containing carbamates 19-d and 19-e and cyclohexyl carbamate
19-c (Figure 3). The positioning of the benzyl substituent of 19-e
resembles that of 19-f. Remarkably, the phenyl carbamate moiety
of 19-d is preferentially placed in the þ1 subsite instead, although
the interaction with F154 still is retained. Just as with the alkylated
derivatives, the positioning of the substituent in subsite þ1
appears to lower the compound’s inhibitory potential. In contrast,
the cyclohexyl carbamate 19-c exhibited a different behaviour: its
preferred docking poses do not match the one of trehalose, high-
lighting the importance of the aromatic group.
Discussion
In our work, we have evaluated a series of 4- and/or 6-O-substi-
tuted trehalose derivatives towards trehalase degradation.
Generally, all compounds were resistant to hydrolysis for both
tested trehalases, with the exception of 6-O-alkylated derivatives
with short carbon chain length (C1-C3). For porcine kidney treha-
lase, as representative of GH37 trehalases, this trend was con-
firmed by docking studies: the hydrolysable 6-O-substituted
derivatives could find a productive fit in the closed (i.e. hydrolyti-
cally active) enzyme structure, whereas that was not the case for
analogues containing larger substituents at this position or for
any of the 4-substituted derivatives. This is consistent with the













aValue not determined, based on observed weak inhibition at 20mM (see
Table 1).
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findings of Asano et al., who pointed out that the enzyme is most
tolerant towards substitutions at the 6-O-position38.
To evaluate whether the non-hydrolysable trehalose derivatives
are still able to bind to the enzyme, inhibition experiments were
performed with the trehalases from porcine kidney (family GH37)
and M. smegmatis (family GH15).
From a pharmaceutical perspective, inhibitors of intestinal gly-
cosidases, including trehalase (GH37 family), can be interesting
and may be orally administered in the treatment of diabetes (type
II) to regulate the absorption of carbohydrates39. A distinction can
be made between transition state analogues and substrate ana-
logues40. The former are inhibitors that optimally bind the transi-
tion state of trehalase, by mimicking the glucosyl-oxocarbenium
ion which is developing during enzymatic action35,40. Examples
are validamycin A 35, validoxylamine A41 36 and trehazolin35 37,
which have IC50 values in the nanomolar range for porcine kidney
trehalase (Figure 4). In contrast, substrate analogues like manno-
trehalose42,43 38, 5-thiotrehalose42 39 and 3,30-diketotrehalose44
40 are mildly potent inhibitors with IC50 values in the range of
0.1–1mM (Figure 4). In comparison, as substrate analogue inhibi-
tors, the presented 6-substituted trehaloses 17-a and 19-f have
IC50 values around 9mM. The observed inhibition could be
explained via docking experiments: binding of 17-a and 19-f was
shown to be possible in the open state of the enzyme via place-
ment of the side chain in the 1 subsite.
Trehalases could also be attractive drug targets in the ongoing
battle against pathogenic microorganisms due to the essentiality
of trehalose and its metabolic derivatives for their survival23.
Trehalose is a building block of the cell wall in mycobacteria and
corynebacteria, as it is a basic component of their glycolipids6,10.
For example, the cell wall of the pathogen Mycobacterium tubercu-
losis contains trehalose-6,60-dimycolate, a toxic lipid that has been
identified as the main virulence factor of tuberculosis and is
responsible for the low permeability of the cell wall, leading to
drug resistance10,45. Interestingly, Shleeva and co-workers investi-
gated the importance of trehalase activity on the resuscitation of
dormant mycobacterial cells46. Validamycin A 35 (Figure 4), a tre-
halase inhibitor that mimics the transition-state, had a negative
Figure 2. Docking of trehalose 1 (left, orange) and validoxylamine 36 (right, green) in the active site pocket of the open enzyme conformation (upper) and the closed
conformation (lower) with surface view of active site pocket (catalytic residues D312 and E496, salmon; side loop Y147-Y159, raspberry; lid loop G506-G519, green).
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effect on the resuscitation of dormant Mycobacterium smegmatis
cells, hereby highlighting the importance of trehalose breakdown
for cell revival46. Based on our obtained results, trehalose
derivatives 2, 17-a, 19-d, 19-e, 19-f, 23-a, 23-c, 23-d, 27, 29 and
31, exhibiting complete inhibition of M. smegmatis trehalase at an
inhibitor concentration of 20mM, are suggested to be mildly
Figure 3. Docking of trehalose derivatives (blue) and validoxylamine 36 (green) in the active site pocket of the open (upper) and closed (bottom) enzyme conform-
ation. An overlay of trehalose (orange) was added for reference. Salmon rectangle: compounds docked in both open and closed conformations, grey rectangle: com-
pounds with aromatic group (catalytic residues D312 and E496, salmon; side loop Y147-Y159, raspberry; lid loop G506-G519, green).
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potent inhibitors with IC50 values down to 0.35mM for 31. To the
best of our knowledge, this is the first report of substrate ana-
logues that inhibit the activity of M. smegmatis trehalase.
Finally, clear differences can be noticed between the two
studied trehalases concerning interaction with our series of trehal-
ose derivatives; generally, M. smegmatis trehalase is more sensitive
to inhibitory effects in comparison to porcine kidney trehalase,
reflecting their classification in different families (GH15 vs. GH37,
respectively). Carrol and co-workers already pointed this out, as it
was found that the transition-state mimic trehazolin35,47, a known
inhibitor of porcine kidney trehalase, had no inhibitory effect
towards M. smegmatis trehalase32 (Figure 4). In our study, this
effect is particularly noticeable in the performance of 4-O-
substituted derivatives; several compounds (2, 21-a, 23-c, 23-d,
23-f, 29, 31) show an interesting inhibition of M. smegmatis treha-
lase (>90% inhibition at 20mM concentration) but lack inhibitory
effect towards porcine kidney trehalase. Notably, the trehalase
hydrolysis-resistant lentztrehalose A 2 inhibited the activity of M.
smegmatis trehalase completely, whereas it only had a poor effect
on porcine kidney trehalase activity (1% inhibition) at the same
concentration, the latter confirming previously reported data25.
This binding selectivity is also reflected in the IC50 values of these
4-O-substituted compounds, which are in the lower- to sub-mM
range (0.35–5.27mM) for M. smegmatis trehalase, but could not
be determined for porcine kidney trehalase (>20mM). Due to this
selective inhibition profile and the hydrolytic stability, these 4-
Table 3. Binding energy (kcal mol1) and the possible presence of a productive conformation determined by simulated molecular docking experiments versus
experimentally observed hydrolysis and inhibition.
Cpd Binding energy open Productive conformation? Inhibition?a Binding energy closed Productive conformation? Hydrolysis?
1 6.88 ± 0.79 YES – 3.36 ± 3.61 YES YES
2 7.39 ± 0.47 NO NO 1.17 ± 2.63 NO NO
17-a 7.21 ± 0.75 YES YES 0.81 ± 6.99 YES YES
19-c 8.33 ± 0.48 NO NO 2.06 ± 1.24 NO NO
19-d 9.02 ± 0.55 YES YES 7.14 ± 2.48 NO NO
19-e 8.85 ± 0.51 YES YES 5.53 ± 1.06 NO NO
19-f 8.80 ± 0.54 YES YES 2.42 ± 1.19 NO NO
21-a 6.76 ± 0.68 NO NO 0.17 ± 4.64 NO NO
36 7.30 ± 0.71 YES YES 2.84 ± 4.59 YES NOb
a>80% inhibition percentage (see Table 1).
bNon-hydrolysable compound (no glycosidic linkage).
Figure 4. Structure of trehalose derivatives that are hydrolysis resistant and inhibitors of trehalases (IC50,PT and IC50,MT; half maximal inhibitory concentration of porcine
kidney and M. smegmatis trehalase, respectively).
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substituted trehalose derivatives could be investigated as poten-
tial selective anti-pathogenic agents that exert a limited inhibitory
effect in the human and/or mammalian gastro-intestinal tract
without being easily degraded by intestinal trehalases.
Conclusions
In this study, a series of trehalose derivatives was successfully syn-
thesised and the effects of their substitution pattern was explored
towards trehalase susceptibility. All compounds were shown to be
fully or strongly resistant to enzymatic hydrolysis, and may thus
have a higher bioavailability than trehalose due to their increased
resistance against trehalase activity in the human gastro-intestinal
tract, which could be promising in eventual drug applications.
Amongst all tested analogues, only trehalose derivatives bearing
short alkoxyl chains on the 6-O-position were marginally hydro-
lysed. A number of the synthesised compounds were found to
have an interesting substantial and selective inhibitory effect
against M. smegmatis trehalase. Studies on the implication of
these trehalose derivatives on the growth of pathogens like M.
tuberculosis are ongoing.
Docking simulations in a trehalase originating from the GH37
family confirmed our experimental findings on porcine kidney tre-
halase. None of the 4-O-substituted derivatives could find a pro-
ductive binding conformation in the open enzymatic state which
supports their low inhibitory effect; they are resistant against
hydrolysis as the closed formation cannot be reached. However,
compounds with substituents at the 6-O-position showed a
greater binding affinity in the open form, explaining their inhib-
ition potential, while a successful fit in the closed form could only
be achieved by the hydrolysable derivatives containing small 6-O-
alkyl groups.
In conclusion, an exploration of 34 trehalose derivatives was
performed by investigating a variety of substituents on the 4- and
6-position. Our work reveals their interaction with two relevant
trehalases, i.e. one from family GH37 and one from GH15, through
in vitro and in silico experiments. In this way, preliminary steps
have been taken to unlock their potential use as thera-
peutic agents.
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